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general introduction 
 
closing capacity of bone defects: scaffolds, 
porosity and growth factors updated
1.1 baCKGRoUND
Bone tissue is one of the tissues needed for transplantation. In clinical practice, many 
patients are treated for skeletal problems in the fields of plastic surgery, orthopaedic surgery, 
maxillofacial surgery and neurosurgery. There is demand for bone due to various reasons, 
for example to fill bone defects caused by trauma or tumour resection, as well as to 
reconstruct congenital malformations and age related osteoarthritis. The use of autologous 
bone grafts is still considered to be the standard method, but there are several major 
disadvantages of this technique, for example: (1) low availability of transplantable tissue, (2) 
postoperative morbidity and (3) lack of functional shape of the transplant. Therefore, several 
alternatives to autologous bone have been investigated. In this respect, basic knowledge of 
the mechanism of bone growth is important because this understanding may lead to 
improve clinical methods of bone repair. Analysing and updating scaffolds and growth 
factor molecules may solve a small portion of this complex puzzle of bone generation. 
1.2 boNE 
‘The hard, largely calcified connective tissue of which the adult skeleton of most 
vertebrates is chiefly composed’ (Webster’s New World Dictionary)
1.2.1 bone structure
Bone provides structural support for the human body, has a protective function and 
is the support system of the internal organs. Mature lammelar bone is composed of 
approximately 93% solid material and 7% water.1
Bone consists of an organic and an inorganic component. The organic component, consists 
of bone cells and extracellular matrix and is composed for 95% of type I collagen. 
Proteoglycans and numerous non-collagenous proteins are present in the remaining 5%. 
The inorganic part constitutes most of the total bone volume by weight (approximately 
70%) and is formed by the crystalline salt which is composed by calcium phosphate in 
the form of hydroxyapatite (HA) (Ca10(PO4)6(OH)2).  
Furthermore, there are two bone types, trabecular/ cancellous bone and compact 
cortical bone. They have different embryologic functions, distributions and biologic 
behavior. Irregular bars, or trabeculae, form organized layers and a mesh filled with bone 
marrow, which finally will be trabecular/ cancellous bone. Compact cortical bone has 
mechanical and protective functions. 
Two embryologically distinct bone types are known: direct intramembranous bone 
and indirect (endochondral) bone. Direct intramembranous ossification occurs in flat 
bones for example the skull, parts of mandible and clavicula. The intramembranous bone 
is derived from direct ossification of mesenchymal precursors. The mesenchymal tissue is 
strongly vascularised and mesenchymal cells are able to differentiate directly into osteoblasts. 
Mineralization takes place in the extracellular organelles (matrix vesicles) in which 
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proteinase, peptidases and alkaline phosphatase (APL) are present.2,3
Endochondral ossification typically occurs in tubular long bones of the skeleton. The bone 
is formed by ossification of a cartilaginous intermediate.4 
Basically, three principal bone cells types, osteoblasts, osteoclasts and osteocytes are 
identified during bone formation and remodeling. Mesenchymal cells first differentiate 
into chondroblasts forming a cartilaginous matrix developing into the direction of the 
bone, which is subsequently mineralized. Osteoclasts then remove part of this mineralized 
cartilage and create space for vascularisation and new bone production by osteoblasts, 
while the remnants of calcified cartilage form a supporting framework.4,5
 
1.3 boNE CEllS
1.3.1 Mesenchymal stem cells
Stem cells can be of mesenchymal origin and are non-hematopoetic cells that are 
capable of both self-renewal and differentiation into, muscle, fat, cartilage, fibrous and soft 
connective tissue and bone cells.5-7 They reside in the bone marrow and can be induced to 
differentiate into various components of the marrow microenvironment. 
1.3.2 osteoprogenitor cells
Mesenchymal stem cells may differentiate into cells that are referred to as committed 
osteoblastic or osteoprogenitor cells. In the later stage of bone formation preosteoblasts and 
transitory osteoblasts are formed. These are both capable of division. Preosteoblasts are flat 
and induce osteoblast cell proliferation and are present in the periosteum and in the marrow 
stroma.8 Recent in vitro studies suggest that under certain conditions, these cells may be 
converted to adipocytes and that this might be a reason for impaired bone formation.9,10
1.3.3 osteoblasts
Osteoblasts are bone-forming and remodeling cells and are made out of mesenchymal 
stem cells through induction by osteoprogenitor cells. The function of these metabolically 
active mesenchymal cells is to produce new bone matrix, ostoid and to mineralize it. 
Osteoblasts produce osteocalcin during the mineralization phase, a major non-collagenous 
protein in bone, containing gamma carboxylated glutamic acid.11
Approximately 10-20% of the osteoblasts will become either osteocytes, covered 
by their own matrix or form a layer of resting cells on the bone surface (flattened bone-
lining cell). Further, the rest of the osteoblasts die through programmed cell death 
(apoptosis).12 
Osteoblasts have receptors for factors that influence bone remodelling and they produce 
many regulators of bone growth. 
1.3.4 osteocytes
Thus, osteocytes descend from osteoblast. When osteoblasts are embedded in the 
bone matrix, the cells are called osteocytes. Osteocytes develop in mesenchyme and are 
networked to each other via long cytoplasmic extensions. They are responsible for 
the routine turnover of bone matrix and the maintenance of the bone. They constitute 
a functional syncytium, which communicates through dentritic processes and gap 
junction.13,14 This syncytium of interconnected cells is probably critical for sensing 
mechanical forces. 
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During differentiation from osteoblasts to mature osteocytes, the cells lose a large 
part of their cell organelles.14 The production of nitric oxide and prostaglandins can be 
stimulated by shear stress, which may mediate the response of bone to mechanical loading.15 
The occurrence of osteocyte apoptosis is consistent with the description of apoptosis as 
an essential homeostatic mechanism for the healthy maintenance of tissues.16
1.3.5 osteoclasts
The osteoclasts are bone resorbing cells that remove bone tissue by removing its 
mineral matrix. Thus, they are responsible for the degradation of bone tissue. Osteoclasts 
are formed by the fusion of mononuclear precursors derived from haemopoetic stem 
cells in the bone marrow.17 
Bone degradation occurs in the extracellular space between the bone matrix and the 
cell border in which the mineral and organic components of the bone matrix are degraded 
by osteoclasts.  
1.4 boNE HEaliNG / boNE fRaCTURE REPaiR
Bone healing takes place in three stages: inflammation, the repair stage and the late 
remodelling stage. It is a complex series of biologic events designed to repair and 
regenerate damaged bone. Two types of bone repair are known, i.e. primary bone repair 
(non displaced bone fragments heal without cartilaginous intermediate) and secondary 
bone/callus (unstable bone segments heal with cartilaginous intermediate) repair. 
Mechanical stabilisation enables new vessel ingrowth, mineralization and osteoid 
deposition. However, absolute immobilisation may cause disturbance in bone healing 
by promoting bone resorption due to stress protection and inhibition of callus formation. 
Controlled axial loading and micromotion have been shown to accelerate fracture repair.18
Although the histologic and ultrastructural characteristics of fracture repair have 
been well studied, the exact sequence of molecular events responsible for these events 
remains unknown. 
When defects are too large and fracture healing is not possible in a spontaneous 
way, the defect is called a Critical Size Defect (CSD). The definition is that the CSD is 
the smallest size of a defect, which does not heal spontaneously, when left untreated 
for a certain period of time.19 In this case, bone grafts or substitutes are necessary. 
Different bone graft materials can be autografts, allografts and xenografts. An 
autograft is bone harvested from the same individual. The major disadvantages in this 
technique are donor site morbidity, low availability of transplantable tissue and lack of 
functional shape of the transplant. An allograft is tissue from one individual implanted 
into another individual of the same species. The disadvantages of allografts include risk of 
transmission of diseases and immunogenicity. Allografts also have less vascularisation, a 
poor degree of cellularity and a higher resorption rate.20,21 A xenograft is tissue harvested 
from one species and implanted into another different species. Xenografts have similarly 
disadvantages as allografts.22
Biomaterials have the potential to replace these natural grafts in the future. Several 
materials have been developed as bone substitutes: natural coral, calcium sulphate, 
hydroxyapatite, tricalcium phosphate, calcium phosphate, bio-active glasses, titanium and 
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polymers. When improving the osteoconductivity of these materials, the defect can be 
closed more easily. By preference, a biomaterial should be biodegradable, immunologically 
inert and mechanical stable. Furthermore, when looking at the economical demands, they 
should be mouldable, user friendly, easy to manufacture and cost-effective.23
Biomaterials are also used as scaffold/carrier material in bone tissue engineering.
1.5 boNE TiSSUE ENGiNEERiNG 
Meijer et all concluded in their review article about cell based bone tissue engineering 
that for successful bone engineering four prerequisites are needed. A sufficient number of 
cells, an appropriate scaffold to seed the cells, factors to stimulate osteogenic differentiation 
in vivo and sufficient vascular supply.24 
Therefore, from the point of bone tissue engineering, the principal aim of generating new 
bone is to restore structural support, as losses are typically limited and the other functions 
of the skeleton can be adequately served by remaining bone.
In 1965 Urist discovered that bone tissue contains specific growth factors that can induce 
bone formation in ectopic places in rabbits.25 This means that stimulation of the body to 
make new bone independent from the surrounding bone tissue is possible, both in a non-
bone environment (ectopical) and in a bone environment (orthotopical). Currently, BMPs 
(Bone Morphogenetic Proteins) are known to be responsible for ectopical bone 
formation.26-30 
With improved purification methods for native BMPs and modern gene technology 
unlimited amounts of recombinant BMPs can be provided, which allow a lot of research to 
the bone inducing potentials of BMPs. Still, the search is continued for the bone graft 
material that is an ideal carrier for BMPs. Also a lot of questions have to be answered 
concerning the release kinetics of BMPs and the optimum dosage for inducing bone 
generation at a defect site. Until recently, no convincing successes were achieved in 
humans.24 
1.6 boNE GRafTS SUbSTiTUTES / SCaffolDS
A lot of prerequisites have been postulated for the ideal scaffold material with regard to 
mechanical properties, biocompatibility and biodegradability, absence of allergic reactions, 
disease transmission, gross architecture, shaping, clinical handling, and regulatory issues. 
It has to be emphasized that none of the currently available scaffold materials meet all of the 
formulated demands. 
A bone graft material is any implanted material that alone or in combination with other 
materials promotes a bone healing response by presenting bioactive, osteoconductive or 
osteoinductive activity. Bioactivity is a property of the ceramic surface which induces 
biological integration of living soft and hard tissues.1 An osteoconductive material promotes 
bone apposition to its surface, which means that the surface characteristics can optimize 
bone ingrowth and in this way enhance bone formation.31 Thus, the bone graft substitute 
supports the growth of bone over its surface. An osteoinductive material needs a rich surface 
charge and affinity for cells to attach and provides a biologic stimulus that induces local or 
transplanted cells to enter a pathway of differentiation, leading to mature osteoblasts.32
115
1.6.1 Calcium Phosphate (Ca-P)
Calcium Phosphate based bone substitutes posses excellent biocompatibitity. Studies 
in the past decade demonstrated that in vivo these materials are non toxic, antigenically 
inactive, non-cancerous and evoke a direct contact with bone without an intervening 
connective tissue layer.33 They can have resorbable and non-resorbable properties. The 
phosphate containing HPO42- and PO43- represent in general the biologically important calcium phosphates. Hydroxyapatite (HA)(Ca10(PO4)6(OH)2) is the most stable form of Ca-P under physiological pH and body temperature and is more similar to bone tissue 
than tricalcium phosphate (TCP). However, resorbability and solubility of TCP is much 
higher compared to HA, which should be considered as non resorbable.34
1.6.1.1 Ca-P cement
Ca-P cements were first introduced in the early eighties. Ca-P cement is a novel 
material for bone repair. It is injectable, can be moulded into the required shape and is 
bone biocompatible.35 The advantages of Ca-P cement include the in vivo moldability 
resulting in a seamless contact of the cement in the surrounding bone.36 The scaffold 
architecture for bone grafting has to allow for initial cell attachment and subsequent 
migration into and through the matrix and for mass transfer of nutrients and metabolites 
and provide sufficient space for development and later remodeling of the organized 
tissue.37 To achieve this, the bone biological properties of Ca-P cement can even be
further improved by creating porosity in the material. The pores create inter-connectivity 
to allow tissue ingrowth and stabilization.38
 1.6.1.2 Porosity of Ca-P cement
The porosity of Ca-P cements can influence the suspension rate of the material and 
its osteoconductive characteristics. Ca-P cements have essentially a microporous structure 
in which the micropores are smaller than 5µm. This pore size is too small for the 
infiltration and ingrowth of cells. 
It is known that porosity has a positive influence on the degradation of Ca-P ceramics and 
determines the natural ingrowth of tissue. The disadvantage of porosity is that it results in 
less mechanical support.
Macropores are larger than 10 µm.34 Macroporosity can be created by Ca-P cement
with e.g. NaHCO3 and NaH2PO4. Gas bubbles will be formed inside the material. As mentioned above, the interconnection between the pores is essential for tissue 
growth throughout the scaffold. The effect of different pore sizes of HA were observed in 
the study of Tsuruga et al.39 Their results indicated that the optimal pore size for
attachment, differentiation and growth of osteoblasts and vascularization is approximately 
300-400 microns.5,39
1.6.2 Titanium
Titanium is well known for its excellent biocompatibility. This is expressed by two 
major observations: 1) a very favorable response of tissues to titanium surfaces, and 
2) the absence of allergic reactions to titanium.40,41 Bone cells and mineralized bone
matrix are laid down on titanium surfaces without interposition of other tissues.40 Porosity 
can be created in the titanium as well. 
Although porous titanium mesh is nondegradable, interconnective porosity and flexibility 
are the advantages of the porous titanium fiber mesh above bulk titanium. Flexibility helps 
presumably to eradicate local forces by distributing the stresses between implant and tissue 
over a larger area.41 The amount of bone ingrowth into the material can be influenced by
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the porosity of the fiber mesh. This porosity can be varied during fabrication and allows a 
more normal restoration of the bone unlike nonporous implant materials.41 Consequently, 
porous titanium fiber mesh offers several advantages over other materials by its uniformity 
and structural continuity, as well as by its strength, high porosity, low stiffness, corrosion 
resistance and high coefficient of friction.42 To enhance the osteoconductive properties of 
the material, seeding stromal bone marrow cells into the mesh porosity or treating the 
titanium mesh with bone growth stimulating factors, like bone morphogenetic protein and 
transforming growth factor-ß1 are a solution.43-46 Also, Ti-mesh has been shown to be an 
effective carrier for both osteogenic cells and BMPs in ectopic bone formation in vivo.46,47 
An alternative approach to the above mentioned ones can be the coupling of bioactive 
ligands, like RGD-peptides, to the titanium mesh surface.48 
1.7 GRoWTH faCToRS iN boNE HEaliNG 
Numerous scaffold materials have been tested with recombinant Bone Morphogenetic 
Proteins (BMPs). These materials include organic and inorganic materials. 
Bone contains several other mitogenic growth factors besides (BMPs) associated with bone 
healing, including Platelet Derived Growth factor (PDGF), Transforming Growth Factor-β 
(TGF-Beta), Insuline Like Growth Factor (IGF-I and II) and basic and acidic Fibroblast 
Growth Factor (bFGF and aFGF).49 
 
1.7.1 bone Morphogenic Proteins
Bone Morphogenic Proteins (BMPs) are growth factors involved in bone growth. 
Growth factors are polypeptides that are generally synthesized by specific tissue where 
they, in very low concentrations, act as local regulators of cell function, including 
cellular migration, proliferation, differentiation and apoptosis. Most growth factors are 
released as high molecular weight precursors, which are split by proteolysis and produce 
active factors, which are generally of low molecular weight. The growth factors elicit 
their action by binding the specific large transmembrane receptors on the cell surface of the 
target cell. 
Bone Morphogenic Proteins (BMP) are members of the so-called Transforming 
Growth Factor (TGF)-ß super family that can exist in 5 subtypes of TGF-ß and 14 
different kinds of Bone Morphogenetic Proteins (BMP). The proteins of the TGF-ß 
superfamily regulate many different biological processes including cell growth, 
differentiation and embryonic pattern formation.50 BMP 1-16 are the presently known 
members of the BMP superfamily. They can be divided into different subgroups according 
to the structural similarity between the molecules within each group. BMP-1 is the only 
BMP that is not a member of the TGF-beta superfamily. 
Various in vitro and in vivo (rodents, dogs, sheep, humans) studies have been done 
to establish the osteoinductive and bone formation enhancing effect of BMP. Especially, 
human BMP-2 and BMP-7 have been investigated extensively for bone engineering 
purposes.51-55 Both are available in large quantities by human recombinant technology. 
BMPs play an important regulatory role in many steps in bone morphogenesis, like 
chemotaxis of osteoblasts, differentiation as well as mitosis of cartilage and bone 
producing cells.56,57 The BMPs have been detected in cells that are involved in fracture 
healing.52 
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During the early phase of membranous-type fracture repair of long bones, BMP 
protein expression is localized in the thickened cambium layer of the periosteum and 
osteoblasts near the fractured bone segments.58 Fracture repair stimulates a periosteal 
reaction and induces the synthesis of BMPs by immature periosteal cells. Initially, within 
several days after the fracture, periosteal cells and osteoblasts show an intense expression of 
bone morphogenetic proteins and their receptors. The expression of bone morphogenetic 
protein decreases when mature lamellar bone appears.58 
Experimental research has shown that BMPs when added to human mesenchymal 
cells, lead to increased matrix production and increased alkaline phosphate and collagen 
I levels. They are the only growth factors with a known ability to stimulate the 
differentiation of mesenchymal stem cells in the chondro-and osteoblastic direction and 
only a subset of BMPs has the unique property of inducing de novo bone formation or 
osteoinduction by themselves.58 Proliferation of the mesenchymal cells is not stimulated.59,60 
BMP has the ability to promote healing of Critical Sized Defects (CSD).
A carrier system of BMP can of course optimize the osteogenic activities of BMP. This to 
prevent rapid release of the BMP proteins from the area to stimulate the osteoprogenitor 
cells for an appropriate duration. Optimally, the subsequent degradation of the carrier 
material should proceed at the same rate as bone regeneration. 
1.7.2 RGD-peptide
Another approach to enhance bone formation is the use of RGD-peptides. Arginine-
glycine-aspartic acid sequence or RGD, is a small peptide ligand, which has high 
affinity for integrins. Integrins, which bind specifically to short peptide sequences like 
RGD, are responsible for cell responses. Recently, a lot of studies have demonstrated 
that these peptide modified surfaces influence cell responses in vitro. In this way, information 
can be transmitted to the nucleus through several cytoplasmic signaling pathways. 
RGD-peptides are known to increase the overall adhesiveness of the surface for 
osteoblasts.61,62 In this way, they can essentially mimic cell attachment activity of the
bone cells.63,64 It has also been suggested that RGD-peptide coating enhances titanium
rod osseointegration in the rat femur.65 
1.7.3 PRP (Platelet Rich Plasma)
Finally, a recently suggested method to deliver growth factors in the bone healing 
process is the manufacturing of Platelet Rich Plasma (PRP). PRP is a volume of 
autologous plasma that has a platelet (thrombocytes) concentration above baseline 
(1 × 109 pl / ml).66 Within thrombocytes/platelets all of the mitogenic growth factors
are present, like Platelet Derived Growth Factor (PDGF), Transforming Growth 
Factor-β1 (TGF-β1) and β2 (TGF-β2), Vascular Endothelial Growth Factor (VEGF), Insulin 
Growth Factor (IGF) and Epidermal Growth Factors (EGF).66-68 These growth factors
are released from platelets after platelet breakdown and are known to play an important 
role in wound healing.67,69-71 
These proteins act on target cells, resulting in the specific stimulation or inhibition of these 
cells. PRP is easily prepared from the patient’s whole blood by centrifugation 
and separation of thrombocytes with the use of a cell separator. Also commercially 
available chair side appliances are available.72-75 Depending on the production process, the 
concentration of thrombocytes in PRP is 3- to 20-fold greater than in whole blood.66 
The positive effect of PRP can be mainly attributed to the effect of TGF-β and PDGF on 
cell proliferation, differentiation and angiogenesis. PRP stimulates the proliferation 
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and differentiation of osteoblasts and proliferation of capillaries.76,77 The clinical use
of platelet concentrates in PRP with autologous bone grafts has been shown to nearly 
double the rate of bone formation and to enhance bone density by 20% in some studies.66 
Recently, the efficacy of PRP combined with a polylactide scaffold and autologous 
bone graft, in a goat mandibular defect model, has been demonstrated.78 The use of such 
scaffolds can further limit donor-site morbidity.  
PRP is autogenous and already been widely used in clinical practice, although there 
is limited evidence and a lot of controversy about its working mechanism. The amount 
of PRP can be counted in a Coulter counter (Onyx/ Bürker). Although discontinuous 
cell separation is adequate for concentrating growth factors from whole blood and there 
is a correlation between the platelets counts in the PRP and the donor blood,79 there is
still considerable variability in the resulting concentrations of these growth factors.80 
In the past years, some promising animal and clinical cases in which PRP treatment 
was applied in combination with autogeneous bone and biomaterials have been 
reported.81-89 Fennis et al. showed that the addition of PRP improved bone healing 
considerably when using cortical scaffolds filled with a particulate cancellous anterior 
iliac crest bone graft in mandibular defects in goats.78,90 Other studies could not confirm 
the positive effect of PRP preparations on bone formation in bone grafts.91-95 
PRP has to be gelatinized to a platelet gel. This is a mixture of fibrogen, factor XIII, plasma 
proteins such as fibronectin and globulin, mixed with a clot initiator (human or bovine 
thrombin) and calcium chloride. The clot initiator forms the PRP into the gel 
which optimize growth factor release. Thrombin converts fibrogen into fibrin, whereafter 
calcium activates factor XIII. A cross-linking fibrin network will be created. This PRP-gel 
can be added to the bone graft or biomaterial. However, various studies have confirmed 
that the combination of PRP with a biomaterial alone does not lead to enhanced bone 
formation.56,96,97 
Although clinical trials suggest that the combination of bone graft substitutes and growth 
factors such as contained in Platelet Rich Plasma (PRP) enhance bone density,66 adverse
effects of the PRP have to be evaluated as well. Finally, there has been some 
concern about a possible carcinogenic effect of PRP related to the stimulation of cellular 
proliferation and its local presence in high concentrations. A possible role of mitogenic 
growth factors in tumor growth has been described, but a carcinogenic effect of PRP is very 
unlikely, since the growth factors are merely differentiation factors and not mutagens. 
Differentiation factors are known to act on cell membranes in order to activate internal 
cytoplasmic signal proteins, which promote normal gene expression.76 
Another consideration is the use of bovine thrombine and the risk of transmitting Bovine 
Spongiform Encephalopathy (BSE) or mad cow disease. Using recombinant human 
thrombine can eliminate this risk.
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1.8 obJECTivE of THiS THESiS
In many fields of medicine, there is a high need for bone graft substitutes. However, 
currently available “synthetic” bone grafts do not meet the requirements to replace the 
autogenous bone grafts and allografts for stable bone creation. On the other hand, calcium 
phosphates have excellent biochemical and biocompatible properties and have been used 
as bone defect filler. In addition, porous calcium phosphate cement appears to be a 
candidate carrier material in the creation of an osteoinductive bone graft substitute. 
Another promising material is titanium fiber mesh, which has excellent biochemical, 
biocompatible and mechanical properties.
The main objective of this thesis was to investigate the feasibility of porous Ca-P 
cement and titanium as a carrier material for growth factors, e.g. BMP in the creation of 
bone graft substitutes in a suitable cranial or critical size defect model. Beside the porosity, 
we hypothesized that the osteoconductive properties of these carrier materials could be 
further enhanced by PRP substitution or surface treatment with RGD.  
Aims of this study were:
•	 Evaluation of the cranial and radial Critical Size Defect (CSD) of a New Zealand white 
rabbit animal model.
•	 Assessment of the suitability of porous Ca-P cement as a scaffold material for bone 
regeneration in cranial non weight bearing situations.
•	 Evaluation of the osteoconductive capacity of the porous Ca-P implants in a rabbit 
radius segmental defect in weight bearing situations.
•	 Comparison of the non-treated open defect size (control) and the defect filled with 
porous Ca-P cement in this weight bearing model.
•	 Measuring the bone strength in this weight bearing model after 12 weeks implantation 
time. 
•	 Evaluation of the different torque/ torsional tests measurements in long bone 
segmental defects. 
•	 Investigation of the suitability of porous calcium phosphate cement as a carrier 
material for rhBMP-2 at orthotopic location (cranial defect).
•	 Evaluation of rhBMP-2 loaded porous Ca-P cement at ectopic site in a rabbit animal 
model compared with the absorbable collagen sponge (ACS). 
•	 Evaluation of the influence of RGD peptide sequence on porous titanium fiber mesh 
and on bone formation itself after different time periods (two, four and eight weeks 
post-implantation).
•	 Evaluation of the bone stimulative effect of PRP in a titanium fiber mesh scaffold on 
autologous bone graft in a weight bearing model.
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Closing CAPACITY OF CRANIAL BONE DEFECTS USING 
POROUS CALCIUM PHOSPHATE CEMENT IMPLANTS 
IN A RABBIT ANIMAL MODEL
iNTRoDUCTioN
Reconstruction of large bone defects (caused by e.g. excision of tumors, trauma and 
congenital malformations), can be difficult to perform and is associated with high 
complication rates. The areas, which have to resist mechanical pressure (weight bearing 
limbs), need extremely solid bone substance for a good reconstruction. 
Standard procedure often involves bone transplantation (autografting). In general, this 
involves long-term surgical procedures with external fixation, which can be hindered by 
complications due mainly to poor local tissue conditions, limitations caused by the amount 
of donor bone material and skin, the size of the defect and the healing process itself. 
Another problem is donor-site morbidity. Many complications such as infection, pain, 
loss of sensibility and haematoma have been described in this area.1 It is not unusual that 
further surgical procedures have to take place due to these complications, often causing 
discomfort and disability.
Bone engineering offers an option to improve bone reconstruction procedures. This 
interdisciplinary field applies the principles of biology and engineering to the development 
of functional substitutes for damaged bone.2 Bone engineering prevents donor-site 
morbidity and creates a scaffold on which it is possible to generate bone mass, this 
can contribute to the formation of lost or lacking bone. 
Our research aimed to find the ideal scaffold material for bone regeneration, focusing 
on Calcium-Phosphate-Ceramics (CPC) developed by Brown and Chow in 1983.3,4 
Calcium-phosphate (Ca-P) cements are well-established materials used for bone repair. 
They consist of a mixture of powder (containing one or more compounds of calcium 
and/ or phosphate salts) and liquid and have a high compatibility and similarity 
with natural bone.5,6,7,8 Ca-P cement is very osteoconductive and biodegradable9,10 and 
furthermore, the cement formation it is easy to shape, injectable and can be maintained 
locally. This is why it is so effective for bone defects with an irregular form. The material 
provides mechanical support and serves as a substratum on which the cells and growth 
factors attach.11 
To improve the quality of this scaffold material, the Department of Biomaterials of the 
University Medical Center Nijmegen has developed a porous Ca-P cement.12 The porosity 
can be created either in vitro or in situ. It is anticipated that the porosity of the Ca-P 
cement will increase osteoconductivity and ensure cell colonisation and flow transport of 
nutrients and metabolic waste to enhance the activity of osteoinductive material.
In order to establish the clinical relevance of a bone substitute material it is useful to 
use a Critical Size Defect (CSD) model. In the literature, various definitions of the CSD 
exist and they indicate discrepancies in the size of the control defect.13,14,15,16 One definition 
is that the CSD is the smallest size of a defect, which does not heal spontaneously when left 
untreated for a certain period of time.17 Another definition is that a CSD is a defect,
which has less than 10 percent bony regeneration during the lifetime of an animal.18
For example, for adult New Zealand red rabbits, a CSD as created in the skull is assumed 
to be 15 mm in diameter after 24 weeks.19 Hollinger et al confirmed that also untreated
15 mm cranial defects created in New Zealand white rabbits show less than 10 percent bone 
regeneration after 48 weeks.20 
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Confirmation of the critical sized nature of a bone defect is always a fundamental 
step in identifying the clinical relevance of bone replacing materials. In this way, the 
direct osteoconductive properties of implant materials can be determined. Therefore, the 
first objective of this study was to evaluate the cranial Critical Size Defect (CSD) of 
a New Zealand white rabbit, which has been defined as the smallest size of a defect that 
does not heal spontaneously when left untreated for a 12 week time period.17 We choose a
non weight-bearing defect for a start, in order to place the implants in weight-bearing 
defects (segmental defects of the radius) in the future. In view of this, circular defects 
with three different diameters (6, 9 and 15 mm) were created in the cranial skull. The 
second objective was to assess the suitability of porous Ca-P cement as a scaffold 
material for bone regeneration, using this rabbit model. A non-weight bearing location 
was chosen for the current study in order to exclude as much as possible interference 
with additional parameters, like the limited weight-bearing capacity of the tested porous 
Ca-P material.
MaTERialS aND METHoDS
Preparation of porous calcium phosphate cement
In total, 30 disc-shaped porous calcium phosphate (Ca-P) cement implants were 
created by the CO2 induction technique.21 The implants were made out of Calcibon® (provided by Biomet Merck, Darmstadt, Germany). This used cement powder consisted 
of: 62.5wt% tricalcium phosphate (α-TCP), 26.8wt% dicalcium phosphate anhydrous 
(DCPA), 8.9wt% calcium carbonate (CaCO3) and 1.8wt% hydroxyapatite (Hap).The cement liquid was a 2% aqueous solution of Na2HPO4. To generate macroporosityof the scaffold, NaHCO3 was added for production of CO2 gas in the cement. The ideal liquid/powder ratio for clinical applications of the cement has been shown to be 
0.35 mL/g.22 A syringe (Sherwood medical monoject 2 mL) was used for delivery of the 
cement.23 One hundred and twenty μl aqueous Na2HPO4 (2% in weight) were addedto the cement, which was placed in this syringe. The syringe was closed with an 
injection plunger and fixed in a mixing apparatus (Silamat® Vivadent, Schaan,
Liechtenstein). Thereafter, 150μl NaH2PO4 (8%) were added in order to create gasbubbles inside the material and to generate macro-porosity. The total porosity of the 
various implants was determined by weighing and using the following formula:
  
Εtot = (1 -     m       ) × 100%
                V × ρhap
Where: Εtot = total porosity (%), m = average mass of the sample (g), V = volume of
the sample (cm3) and ρhap = density of hydroxyapatite (g/cm3).
In this way, the total porosity of the 6, 9 and 15 mm implants was calculated to be 
71%, 74% and 74% respectively. The cement implants have an average pore diameter of 
150 μm12 Besides, a previous study already confirmed that. The newly formed cement
was injected immediately into cylindrical Teflon moulds with three different diameters 
(6, 9 and 15 mm), to ensure a standardized shape of the implants. Subsequently, the samples 
were placed into an oven at 50°C for one hour. Afterwards, the surface of the discs
was sandpapered to ensure the standardized height of 3 mm. Finally, the discs were 
sterilized by autoclaving for 15 minutes at 121°C. 
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Surgical procedure
In total, 40 adult female New Zealand rabbits (mean weight: 3334 gr; “de Vaan” farm, 
Bergharen, The Netherlands) were used. National guidelines for the care and use of 
laboratory animals were observed. Surgery was performed under general inhalation 
anesthesia. The anesthesia was induced by an intravenous injection of Hypnorm®
(0.315 mg/ml fentanyl citrate and 10 mg/ml fluanisone) and atropine, while maintained 
by a mixture of nitrous oxide, oxygen and isoflurane through a constant volume ventilator. 
To reduce the peri-operative infection risk, antibiotic prophylaxis (Baytril 2.5%; 
Enrofloxacin, 5-10 mg/kg) was given to the rabbits. After anaesthesia, the animals were 
immobilized on their abdomen: The cranium was shaved and disinfected with povodine-
iodine. From the nasal bone to the occipital protuberance, a longitudinal incision was 
made in the skull. Then, a midline incision was created in the periosteum, the periosteum 
was removed gently and lifted off the parietal skull with a blunt instrument. Subsequently, 
defects of different sizes were prepared with a dental-trephine bur (Table 1).
Group Cranial size defects
I (n=10) 6 mm (pCa-P)
6 mm (control)
II (n=10) 9 mm (pCa-P)
9 mm (control)
III (n=10) 15 mm (pCa-P)
IV (n=10) 15 mm (control)
TABLE 1: Design of the experiment: number of animals and defect size.
The drill depth was always kept limited and the loosened cranial bone discs were 
removed carefully. In this way, full thickness holes were created without damaging the 
dura. The bone preparation was carried out using low rotation speed (max. 450 rpm) 
and using continuous internal cooling with physiologic saline. After these procedures, 
porous Ca-P-cement implants were inserted in the therefore chosen defects and the 
periosteum (Figure 1) and skin was closed (tensionless) using a vicryl 4.0 suture. 
Perioperativily, all the rabbits got Temgesic 0.05 mg/kg twice a day during two days for 
pain prevention. 
As described in Table 1, a total of 40 animals were divided into four groups. Group one 
received 6 mm defects on both the right and left side of the cranium. The implant was 
placed alternately in the right or left defect, while the contralateral side was left open to 
serve as the control. Group 2 received 9 mm defects on the right and left side of the 
cranium, with the implant placed alternately in the right or left defect, and the contralateral 
side left open as the control. The third group received only one defect with a diameter of 
15 mm in the middle of the cranium, because the skull is too fragile to bear two 
defects of this size. These single defects in the third group were filled with the 15 mm 
cement implants.
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Therefore there was an additional fourth group in which 15 mm defects were made in the 
cranium, which were left open, to serve as the control group of group III. The 15 mm 
defect size was chosen because it is assumed to be a critical sized defect (no spontaneous 
healing within 12 weeks17, while the 5 and 9 mm defects were included as follow-up defects 
to evaluate the final osteoconductive properties of the porous Ca-P cement.
The rabbits were sacrificed 12 weeks postoperatively, and the skull containing the 
implants was used for radiological, histological and histomorphometrical evaluation. 
Evaluation
Radiographic analysis
For all animals, an X-ray of the cranium was made after 12 weeks. The radiographs 
were made with a Siemens mobilett X-ray machine. The healing (closure) of the control 
defects of all groups were compared. 
FIGURE 1: Left: Empty 15 mm cranial defect of the rabbit. 
 Right: Insertion of the porous Ca-P cement disc in the cranial defect. 
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Histological and histomorphometrical evaluation 
Directly after retrieval, specimens were fixed in 4% buffered formalin solution, 
dehydrated in a graded series of alcohol and embedded in methylmethacrylate (MMA). 
After polymerisation, non-decalcified thin (10 µm) transverse sections of the implant were 
prepared (at least three of each implant) using a modified sawing microtome technique.24 
Methylene blue and basic fuchsin were used for staining the sections. Histological 
examination of the slides was carried out using a light microscope (Leica BV, Rijswijk, the 
Netherlands) and using a concise description of the observed tissue reaction, i.e. histological 
appearance of the stability or degradation behavior of the implant, surrounding tissues 
and the tissue that has grown inside the implant porosity.
This histomorphometrical analysis was performed using computer based image 
analysis techniques (Leica® Quin Pro-image analysis system). Measurements were taken 
from three sections per porous Ca-P implant, and the results pooled to obtain an average 
for each implant, which was then used in the statistical evaluation. 
The following parameters were used for digital analysis of the the cranial implants:
•	 The surface of the area where the implant is inserted, which is called the region of 
interest (ROI).
•	 The cement surface area. The cement surface area included micro-porosity of the cement, 
since pores smaller than 1 µm could not be distinguished histomorphometrically from 
cement particles.
•	 The bone surface area (%). This is the % of bone in the ROI.
•	 The macro-porosity (%), this is the ROI minus the cement surface area and bone 
surface area.
•	 Pore fill by bone (%), expressed as percentage of pore surface area occupied by bone.
Statistical analysis
Measurements from the histomorphometrical analysis were statistically evaluated 
using a One-Way Analysis of Variance (ANOVA) test25 using GraphPad® Instat 3.05 
software (Graphpad Software Inc., San Diego, CA, USA). Differences were considered 
significant at p-values less than 0.05.
RESUlTS
Experimental animals:
In this study, three of the 40 animals did not survive the surgical procedure. One rabbit 
of the 9 mm cranial defect group + control group (after 23 days), and two rabbits of the 
porous Ca-P 15 diameter group (group III) died within 2 days of surgery. Their cause of 
death could not be determined to dural bleeding or oedema. This resulted in the following 
final numbers of retrieved animals per group: n=10 (Group I), n=9 (Group II), n=8 (Group 
III) and n=10 (Group IV). At retrieval, no inflammatory signs or adverse tissue reaction 
were observed. The porous Ca-P implants were clearly visible in the skull of the rabbit 
and covered by periosteum. 
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Radiographic analysis
The X-rays made after sacrifice suggested that two of the 6 mm control defects were 
closed after 12 weeks. In the 9 mm defects, three control defects appeared to be closed. 
In the 15 mm control group, all defects were still open and it was remarkable that the 
shape of the remained defect showed an oval central uncalcified area (Figure 2A). 
In all Ca-P filled defects, the porous implants were always visible. In the 6 and 9 mm 
group, no signs of implant fracture or damage were observed. On the other hand, in the 
15 mm group fracture lines were present (Figure 2B).
Histology
Histologically there were no signs of inflammatory cells, necrosis or foreign body 
reaction. The cement was clearly visible and all control defects could be detected. All 
implants were surrounded by a thin fibrous capsula. Overviews of the sections of each 
group are shown in Figures 3 and 4. A more detailed picture of the bone formation in the 
porous Ca-P cement is shown in Figure 5.
Group I (6 mm)
After 12 weeks all of the porous Ca-P discs were completely covered and filled with bone 
(Figure 3A). Bone formation was seen in the pores and blood vessel ingrowth was present 
over the whole of the implant. Bone ingrowth was always seen to occur from one defect 
edge to the opposite one. It was characterized by the occurrence of osteoblasts, osteocytes 
and osteoclasts. There was excellent bone attachment to the surface of the porous Ca-P 
cement along the original defect, thus demonstrating a clear bone bridging aspect. Of the 
control defects, 3 of the 10 defects were left open after 12 weeks (Figure 4A). Both in open 
and closed defects, the ingrowth of new bone had proceeded form the defect walls to the 
center of the defect. The newly formed bone had a trabecular appearance and no discern 
could be made between the original and newly formed bone, which made it impossible to 
locate the previously created drill walls. In the open defects, the center of the defect was 
filled with fibrous tissue.
A B
FIGURE 2: Radiographic analysis.
A: 15 mm open control defect, which is still open after 12 weeks implantation. 
B: 15 mm porous Ca-P cement implant with a white aspect in which fracture lines are visible 
 (also after 12 weeks implantation time).
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FIGURE 3: Stained section of the 6, 9 and 15 mm porous Ca-P cement implant (original magnification 1.6x, 
bar represents 1 mm) in respectively A, B and C. The porous Ca-P in the middle has a dark aspect surrounded 
by bone formation developed over the implant.
A
B
C
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FIGURE 4: Stained section of the 6, 9 and 15 mm control defect which are still open after 12 weeks 
implantation (original magnification 1,6x, bar represents 1 mm) in respectively A, B and C.
A
B
C
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Group II (9.0 mm)
In all the animals, bone formation was present over the whole of the porous Ca-P 
implant. Bone was seen also in the macropores, without any gap formation (Figure 3B). 
Osteocytes, osteoblasts and osteoclasts were visible in the implants, and a bone bridging 
aspect was seen, similar to the first group. Blood vessel ingrowth was present as well. 
In contrast to the first group, loose fragments of Ca-P were observed. 
Of the control defects, three were closed and the other six were still open after 12 weeks 
(Figure 4B). The appearance of the closed and open defects was similar as described above 
for the 6 mm defects. 
Group III and IV (15 mm)
In seven of the eight animals of group III bone bridging was present over the whole of 
the implant similar to that of groups I and II (Figure 3C). As in the first two groups, 
osteocytes, osteoblasts and osteoclasts and invasive blood vessel ingrowth were present in 
the implants. On the other hand, fracture lines and loose Ca-P fragments in the cement 
were now visible in about 90% of the prepared histological sections. 
All control defects (n=10) were open after 12 weeks´ implantation time (Figure 4C). 
Relative less bone ingrowth was observed compared with the 6 and 9 mm control defects. 
As a consequence, a larger central open area was observed, which was again filled with 
fibrous tissue. The morphology of the ingrown bone and the remodeling of the drill walls 
were similar to the 6 and 9 mm control defects.
FIGURE 5: Stained section of the 
porous Ca-P (original magnification 
40x, bar represents 25 µm). Direct 
apposition of bone on the porous 
Ca-P cement surface is observed. 
C=Cement, P=Pore, B=Bone, 
Ob= Osteoblast, Oc= Osteocyte.
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Histomorphometry
A histomorphometrical analysis of bone ingrowth was only done for the cement filled 
defects, because it was impossible to locate the original drill walls. As a consequence, 
a proper definition of the Region of Interest was not allowed, which hampers correct 
measurements. The results of the histomorphometry analysis of the three porous Ca-P 
implant groups are listed in Table 2. 
Groups with pCaP implants
12 weeks implantation time n
bone Surface 
area (%)
Postimplantation 
macro-porosity (%) Porefill (%)
I: Porous Ca-P 6 mm 10 17 (±7%) 27 (±7%) 60 (±14)%
II: Porous Ca-P 9 mm 9 18 (±6%) 37 (±5%) 48 (±14%)
III: Porous Ca-P 15 mm 8 17 (±3%) 41 (±6%) 43 (±11%)
P value 0.95 0.0002 0.028
TABLE 2: Histomorphometrical results of post-implantation macro-porosity, bone ingrowth, porefill and 
P-value; percentages for the three porous Ca-P implant groups after 12 weeks.
Comparison of the data shows that no difference in bone surface area existed for the 
three different implant diameters. On the other hand, a statistical significant difference 
(p<0.05) was seen in pore fill percentage between the 6 mm and 15 mm group (60 ±14% vs 
43 ±11%) after 12 weeks of implantation. Pore fill percentage was similar for the 9 mm and 
15 mm implants. This corroborated with the calculated macro-porosity (= empty space 
after ingrowth of bone into the cement pores) as left in the implants. Significantly less 
(p<0.05) open space was left in the 6 mm implants compared with both the 9 mm and 15 
implants, while no difference in post-implantation macro-porosity was found between the 
9 mm and 15 mm implants.
DiSCUSSioN
As a basis for assessing the suitability of porous Ca-P cement as a bone regeneration 
material this experiment aimed to determine the cranial Critical Size Defect (CSD) of a 
New Zealand white rabbit. The results showed that defects of 15 mm failed to heal 
spontaneously; after 12 weeks all control defects with a diameter of 15 mm were still open.
It is known that the size of a CSD is depending on the breed and age of the used 
experimental animal model as well as the location of the defect. Therefore, in the current 
study, bone defects with varying diameter were created in the skull of only 3-month old 
New Zealand white rabbits. Determination of the critical defect size in this model and 
location can be valuable for other researchers studying the osteoconductive material 
goods of implants, although some discussion has arisen over whether testing an implant 
or graft in a non-critical size defect may also be meaningful, because delayed healing 
may occur due to the implant acting as a physical barrier.26 Nevertheless, our results 
corroborate with studies as performed by Frame et al19 (New Zealand reds) and Dodde27 
37
2
(New Zealand whites, despite the fact that in these studies the animals were older (4 to 10 
months compared to the 3 months old rabbits in our study). They also concluded that a 
defect size of 15 mm was the CSD.
The radiographs of the 15 mm control revealed that oval shaped gaps were left in 
the direction of the cranial skull lines (Figure 2A). Remarkably, this is the place where the 
sinus of the dura is located. It is known that the bone healing process is delayed when there 
is a haematoma in situ, and we assume that this could have been be the case in this 
experiment. Apparently, prevention of blood clot formation is important to stimulate the 
bone engineering process. 
The X-ray data of the 6 mm control defects also showed a discrepancy compared 
with the histological observations, because the radiographs suggested that more defects 
were closed than seen in the light microscopical sections. Evidently, this is due to the fact 
that an X-ray image is a 2D representation of a 3D object. Consequently, overlapping 
structures and small differences in radiopacity of the ingrown tissue result in overestimation 
of defect closure.
Further, this study aimed to assess the characteristics of our scaffold material (porous 
Ca-P cement) when implanted in this animal model. Bone growth was seen in all three 
defect sizes in which implants were inserted and always seemed to extend from one 
defect edge to the opposite one. In view of this, the results provide evidence that porous 
Ca-P cement shows good osteoconductive properties without any sign of delayed or 
compromised healing when used for implants placed in a cranial defect of a rabbit. This 
was also confirmed in a previous study by Ruhé using the same animal model, in which 
8 mm defects were made with an implantation time of 2 and 10 weeks.11 Only, one of
the 8 animals in the 15 mm porous Ca-P group showed no complete bridging of the skull 
defect. Strikingly, there was a large air bubble in this implant, which may be the reason 
that the formation of the bone bridge was delayed.
Also, all implants remained located in the created defect and maintained their 
shape and stability, with no signs of migration of the implant. Despite the overall good 
survival rate, two of the rabbits of the 15 mm defect group who received an implant died 
shortly after surgery. The reason for this could be the high pressure of the large diameter 
scaffold, which creates a high intracranial pressure. Alternatively, oedema, infection or 
intracranial bleedings, may have been the cause of death, although signs of these were not 
detectable during post-mortem examination. The death of one 9 mm defect rabbit was 
supposed not to be related to the surgery, because the animal died about 3.5 weeks after the 
installation of the implant.
As already mentioned, the defects in which porous CaP cement implants were placed, 
showed a complete bone bridging, as seen from the histological examination. We also 
noticed that the bone formed in porous Ca-P was covering a larger distance of the created 
defect compared to the open control groups. In contrast, the control defects showed bone 
formation only at the edges. Unfortunately we were not able to measure the amount of bone 
formation of the control groups because drill holes were not detectable in the histological 
sections. Marking the location of the drill holes of the control group with a metallic pin can 
be a way to overcome this in future experiments. 
Previous studies described the degradation of Ca-P cements during implantation in 
bone defects.28 Nevertheless, no clear sign of cement degradation was observed in our 
histological sections. Although, this observation agrees with another recent study of 
our group using the same cement composition and implant location, it contradicts with the 
results of Perez del Real et al, who used also the same cement composition and porosity 
preparation technique.21 However, in this study, the cement was installed in defects
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created in the trabecular bone of the femoral condyle of goats. Besides physico-chemical 
properties, the degradation rate of Ca-P ceramics is dependent on the local remodeling 
activity and bone conditions of the implant site. We suppose that this explains the current 
difference in results. Of course, it has to be noticed that poor mechanical properties are a 
disadvantage of the maintenance of highly porous Ca-P ceramic. This can be the reason for 
fracture lines in the 15 mm implants (visible during histological and radiological analysis 
(Figure 2B and 3C), which can be created during head injury against the cage walls as 
caused by the rabbit itself. Perhaps, a possible solution for this problem can be found by the 
preparation of mechanically stronger Ca-P cement composites, including the use of an in 
vivo degradable porogen, which is replaced during degradation by ingrowing bone.
 
CoNClUSioN
The study showed that 15 mm is the Critical Size Defect (CSD) in an adult New Zealand 
white rabbit. The results also confirm that within the limitations of the study design, i.e. 
no comparison with other implant materials, porous Ca-P cement implants demonstrate 
excellent osteoconductive properties in non weight-bearing situations and bone bridging 
takes place over the total implant diameter. 
Acknowledgement: This study has been supported by the NWO-AGIKO foundation.
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TORQUE TESTING AS A METHOD TO DETERMINE THE 
REGENERATION OF SEGMENTAL BONE DEFECTS IN RABBITS 
PROVIDED WITH POROUS CALCIUM PHOSPHATE CEMENT
iNTRoDUCTioN
Reconstruction of large segmental bone defects caused by excision of tumors, trauma 
and congenital malformations, are complex procedures for reconstructive surgeons. 
Especially areas, which have to resist a lot of mechanical load (like weight bearing limbs), 
are difficult to reconstruct. It is not uncommon that a second or a third surgical procedure 
has to be performed due to complications, e.g. infection, pain, loss of sensibility and 
hematoma. Problems that occur during the healing process can even lead to amputation 
of the limb.
This study was focused on the use of calcium phosphate (Ca-P) cement, as a synthetic 
bone grafting material. An important advantage of this material is that can be injected and 
shaped, which makes it very effective for the restoration of large bone defects with an 
irregular or abnormal shape. After setting, the material provides mechanical support and 
serves as a scaffold upon which the cells attach, proliferate and undergo differentiation due 
to its high similarity and compatibility with natural bone.1-4 In addition, Ca-P cement can 
be provided with a porosity, which is anticipated to increase the osteoconductivity and 
to enhance the degradation of the material.5,6 Also, the material can be used as a delivery 
system for the supplementary release of growth factors to further boost bone formation.7 
In order to determine the clinical relevance of Ca-P cement as a bone substitute 
material in a weight-bearing situation, the current study aimed on the use of a rabbit 
segmental defect model. The mid-diaphyseal radius was chosen as the area in which to 
create non-critical as well as an assumed Critical Size Defect (CSD). It is claimed that 
this model does not need any kind of internal or external fixation because the maintained 
intact ulna provides sufficient stability.8,9,10-12 A CSD is defined as the smallest size of
a defect, which does not heal spontaneously when left untreated for a certain period of 
time.13 There is a lot of variation in literature in the definition of a segmental CSD as
made in rabbits.
The CSD of a radius or ulna, has been defined as 15 mm or 20 mm.8,9,14-19 In this
study, defect sizes of 5, 10 and 15 mm were used. The defects in both radii of each 
animal, were left open or filled with a tubular shaped porous Ca-P cement implant of 
the same size. The hypothesis was that the empty 15 segmental defects would stay open 
during a 12 week healing period. This in contrast to the porous Ca-P cement filled 
15 mm defects, which were supposed to become closed due to the osteoconductive 
properties of the cement material. Five and 10 mm defects without Ca-P cement implants 
were also included as controls. Further, it was decided to evaluate the final bone regenerative 
capacity as present in all conditions not only by X-ray imaging and histological analysis, but 
to put special emphasis on mechanical testing as a methodological approach to determine 
final bone regeneration. For the mechanical studies, a torsional approach was used, which 
is considered as an appropriate method to measure the strength of the healed 
bone in long bone segmental defect models. A review of the literature shows that such a 
torque test can be performed in different ways.8,20,21 Some studies test the total
ulna-radius complex, while others separate the radius or ulna and test the single bone alone. 
It can be questioned whether such a separation is feasible without damaging the 
regenerated tissue. Therefore, we decided to maintain the complete ulna-radius complex 
during the torque assay. 
44
MaTERialS aND METHoDS
Preparation of porous calcium phosphate cement
In total, 30 porous calcium phosphate (pCa-P) cement implants were created by a 
CO2 induction technique.22 The implants were tubular-shaped with a diameter of4.2 mm and length of resp. 5, 10 and 15 mm. Specific designed Teflon moulds were 
used to prepare the implants. The implants were made out of Calcibon® (provided by
Biomet Merck, Darmstadt, Germany). This cement consists of a mixture of 62.5wt% 
tricalcium phosphate (α-TCP), 26.8wt% anhydrous dicalcium phosphate (DCPA), 
8.9wt% calcium carbonate (CaCO3) and 1.8 wt% hydroxyapatite (HA). The ideal liquid/powder ratio for clinical applications of the cement has been shown to be 0.35 mL/g23. 
To create porosity NaHCO3 was added to the cement powder. All components (0.5 G of standards powder plus 0.05 g of NaHCO3) were placed into a syringe (Sherwood medical monoject 2 mL) with aqueous Na2HPO4 (2%). The syringe was closed with an injection plunger and fixed in a mixing apparatus (Silamat® Vivadent, Schaan, Liechtenstein). After 
a mixing time of 15 sec, the plunger was removed and NaH2PO4 (8%) aqueous solutionwas added. Thereafter, the syringe was shaken again for 2 sec. Finally, the mixed cement 
was injected immediately into the respective Teflon moulds to ensure the standardized 
shape of the implants. Subsequently, the samples were placed in an oven at 50°C for 1 h.
After cooling, the implants were sandpapered to ensure a standardized size. 
Subsequently, the specimens were sterilized by autoclaving for 15 minutes at 121°C. 
Surgical procedure
A total of 30 adult female New Zealand white rabbits (2, 5-3, 5 kg), 6 months of age, 
were used. National guidelines for the care and use of laboratory animals were respected. 
The rabbits were divided in 3 groups (5, 10 and 15 mm defects with or without pCa-P 
implant) as described in Table 1.
Group number Segmental defects of 
the radius (bilaterally)
I n=10 (1†) 5 mm (Ca-P +control)
II n=10 10 mm (Ca-P +control)
III n=10 (1†) 15 mm (Ca-P +control)
TABLE 1: Design of the experiment showing the number of animals and bilateral defect sizes.
Surgery was performed under general inhalation anesthesia. The anesthesia was 
induced by an intravenous injection of Hypnorm® (0.315 mg/ml fentanyl citrate and
10 mg/ml fluanisone) (Abbeyvet Export Ltd, Leeds, UK) and atropine, and maintained 
by a mixture of nitrous oxide, isoflurane, and oxygen through a constant volume 
ventilator. To reduce the peri-operative infection risk, antibiotic prophylaxis (Baytril®
2.5% (KPV Pharma, Kiel, Germany) was given. Preoperatively, all rabbits received 
Finadyne® (Schering-Plough, Segre, France) 0.02 mg/kg twice a day during two days
for pain treatment. An extra 40 ml fluid was administered before surgery to prevent 
dehydration. 
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After induction of anesthesia, the animals were immobilized in a prone position. In 
each animal the front legs were shaved and disinfected with povidone-iodine. A 4.5 cm 
longitudinal skin incision was made at the dorsal part along the radius. After dissecting 
the muscles, the radius was exposed. The periosteum was partially pushed off and a 5, 10 
or 15 mm segmental defect was created in the mid diaphyseal part of the radius using a 
diamond-bladed dental drill with continuous saline cooling.
In all groups, bilateral segmental radial defects of the same size, were made in both radii. 
The porous Ca-P cement implants were pressed into place, according to a randomization 
scheme in the left or right limb, while the other limb served as the control group (Figure 1). 
After finishing this procedure, the muscle layers and the skin were closed in separate 
layers with a Vicryl 4.0 suture.
The rabbits were sacrificed 12 weeks postoperatively for radiological, mechanical and 
histological evaluation. Of each experimental group, 6 of the ulna-radius complexes were 
used for torque testing. The remaining ulna-radius complexes were taken directly for 
histological evaluation. Further, the specimens as subjected to mechanical testing were 
after application of the torsional load also prepared for histological analysis.
FIGURE 1: Implantation of the scaffold in the radius. 
Radiographic analysis
A medio-lateral X-ray of the ulna-radius complex was made immediately after 
surgery (day 0), at 2 weeks and 12 weeks postoperatively. The radiographs were made with 
a Siemens Mobilett X-ray machine. The obtained X-ray images were only used for a 
subjective description of the bone healing characteristics such as callus formation, quality 
of union and bone remodelling in the three different experimental groups.
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Mechanical testing (Torque test) 
After harvesting, the ulna-radius complexes of 18 rabbits (six of each experimental 
group) were dissected free of all soft tissue. The ulna and the radius were connected to 
each other due to the fibrosis and new bone formation. A dental plaster was used to fix 
the specimen for mechanical testing (Figure 2A, 2B). Therefore, both ends of the forearm 
were placed in square formed moulds, which were filled with dental plaster. After setting, 
these square models fitted precisely in the torque apparatus (Instron, Norwood, USA). 
Before mechanical testing, two transcortical cuts were made as distal as possible at the 
lateral ends of the ulna using an oscillating saw. This was done to eliminate the mechanical 
contribution of the ulna and to isolate the radius during torque testing. Separation of the 
radius from the ulna was not an option due to ulnar hypertrophy, scar tissue formation 
and fibrous fusion.24 The experimental groups were also compared to twelve non-operated 
complete bone samples as retrieved from rabbits of the same age.
An Instron torque apparatus was used to measure the maximum stress, which could 
be submitted to the ulna-radius complex (values of ultimate torque/ torque at failure) with 
or without porous Ca-P cement. The torque speed was 5 mm/minute. The angular 
displacement at torque failure could also be extracted from the data. With these 
measurements the energy absorbed and the stiffness of the specimens were calculated:
Torque = Force × real distance (N.mm)
Energy = Force × real distance × degree (N.mm × °)
Stiffness = Torque / degree (N.mm / °)
FIGURE 2A: Torque test measurement. The ulna-radius complex fixated in the dental plaster. 
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Histological evaluation 
All the samples for histological examination (also the specimens as included after 
torque testing) were fixated in 4% phosphate-buffered formalin solution, dehydrated 
in a graded series of ethanol and embedded in methylmethacrylate (MMA). After 
polymerization, thin longitudinal sections (10 μm) were prepared (at least three per 
implant) in a transversal plane with a sawing microtome technique.25 These sections
were stained with methylene blue/ basic fuchsin and examined with a light microscope 
for concise histological description (Leica BV, Rijswijk, the Netherlands).
Statistical analysis
All data are reported as means and standard deviations. Measurements from the 
mechanical testing were statistically evaluated using a paired T-test (GraphPad® Instat
3.05 software, San Diego, CA, USA).26 Differences were considered statistically
significant at p-values less than 0.05.
FIGURE 2B: Torque test measurement. An Instron apparatus was used to measure the maximum stress as 
could be submitted to the bone structure.
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RESUlTS
In this study, two of the animals died directly after the surgical procedure (one 
animal of the 5 mm defect group and one of the 15 mm defect group). The remaining 
(n=28) survived the 12 weeks and were able to walk within three hours after surgery. 
The rabbits remained in good health, did not lose weight, did not show any direct 
wound complications, and the total ulna-radius complex could be taken out for further 
investigation at the end of the study.
Radiographic analysis
The radiographs taken directly after surgery confirmed that all implants were 
installed correctly. At two weeks, the X-rays showed a minimal amount of bone healing 
in all three groups. 
After 12 weeks implantation time, the radiographs showed bone bridging over the 
total length of the defects of all three porous Ca-P cement groups (5, 10 and 15 mm 
defects) (Figure 3B). The porous Ca-P cement implants also remained in place according 
to X-ray examination and were clearly visible in the radius of the rabbit. One of the 
15 mm implants showed a fracture line through the implant.
In the control group (no implants), all 5 mm defects were closed. In group II (10 mm), 
one out of 10 control defects was still open. In the third group (15 mm), 7 out of 9 control 
defects appeared to be still open (Figure 3A-2). Results are presented in Table 2. The two 
15 mm control defects that were closed, showed a tiny bone bridge at the ulnar side of 
the radius. 
FIGURE 3A-1: Control 15 mm after 2 weeks. 
FIGURE 3B-1: 15 mm porous Ca-P cement after
2 weeks. 
FIGURE 3A+B: Radiographic analysis of the 15 mm implant after 2 and 12 weeks of implantation. 
FIGURE 3A-2: Control 15 mm after 12 weeks. 
FIGURE 3B-2: 15 mm porous Ca-P cement after
12 weeks. 
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X-ray after 12 weeks Closed open
5 mm (n=9) Ca-P 9 0
5 mm (n=9) control 9 0
10 mm (n=10) Ca-P 10 0
10 mm (n=10) control 9 1
15 mm (n=9) Ca-P 9 0
15 mm (n=9) control 2 7
TABLE 2: Radiology results after 2 and 12 weeks. The numbers of open and closed defects are presented.
Mechanical testing (Torque test)
Of each experimental group 6 ulna-radius complexes were used. In addition, the 
same test was carried out with an intact bone group as retrieved from rabbits of the 
same age (n=12).
During the torque tests, 2 animals of the 10 mm group and one of each 15 mm 
group were excluded of this paired test, due to technical failure during the torque test 
in one of the ulna-radius complexes (fracture of the dental plaster as used for the fixation 
of the ulna-radius complex or unstable fixation of the ulna-radius complexes in this dental 
plaster). The ultimate forces and distances were measured and the calculated torque, theta, 
stiffness and energy were calculated (see Table 3). 
Statistical analysis of the torque measurements using the T-test showed that the 5 and 
10 mm defects with our without pCa-P implants achieved similar values at 12 weeks 
of implantation (p value in the 5 mm group (n=6) was 0.13 (95% confidence interval 
of difference: -69.3 and 399.2), in the 10 mm (n=4) group p=0.71 (95% confidence 
interval of difference: –472.5 and 365.5). There was also no statistically significant 
difference with the retrieved non-operated bone samples. Further comparison suggested 
that the torsion data for the 15 mm open defect were lower compared with the filled 
15 mm defect as well as the non-operated specimens (15 mm group (n=5) p=0.11 (95% 
confidence interval of difference: –499.2 and 73.3). However, a significant difference 
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could only be proven for the non-operated samples (p=0.03).  
force N 
(±SD)
Real 
distance 
(±SD)
Torque 
N.mm 
(±SD)
Theta 
Degrees 
(±SD)
Stiffness 
N.mm/
degrees 
(±SD)
Energy 
N.mm × 
degrees 
(±SD)
Ca-P 5 mm  8.8(±2.8)
21.6
(±5.9)
469.0
(±152.2)
23.2
(±6.3)
20.2
(±3.7)
10868.6
(±5873.7)
Open 5 mm 10.7 (±3.0)
25.8
(±5.2)
634.0
(±106.7)
27.6
(±5.6)
22.9
(±8.0)
17526.0
(±3174.2)
Ca-P 10 mm 11.7 (±2.4)
26.1
(±2.9)
628.1
(±129.5)
27.9
(±3.1)
22.5
(±4.8)
17545.3
(±4548.8)
Open 10 mm 11.5 (±4.0)
21.2
(±3.8)
616.3
(±212.9)
22.7
(±4.0)
27.2
(±6.9)
13992.67
(±6878.6)
Ca-P 15 mm 9.5(±4.4)
20.2
(±5.2)
508.3
(±238.4)
21.6
(±5.5)
23.5
(±7.6)
10995.4
(±8118.8)
Open 15 mm 5.7(±3.4)
18.2
(±15.4)
305.0
(±181.6)
19.5
(±16.5)
15.6
(±6.4)
5947.2
(±8002.4)
No defect 10.6(±2.3)
23.7
(±4.3)
566.0
(±123.2)
25.4
(±4.6)
22.3
(±6.3)
14387.7
(±5262.4)
TABLE 3: Torque test results. Torque, Stiffness and Energy are calculated.
Torque = Force × real distance (N.mm)
Energy = Force × real distance × degree (N.mm × °)
Stiffness = Torque / degree (N.mm / °)
Histology
Group I (5 mm)
After 12 weeks, residues of the Ca-P were visible, but not in all the samples. One of 
the implants showed an old hematoma, without signs of infection. Ingrowth of blood 
vessels was observed throughout the porosity of the pCa-P implants. At the implant-ulna 
border, new bone formation had occurred, which resulted in fusion between the pCa-P 
implant and ulnar bone. Also at the original defect border, the newly formed bone was in 
contact with the porous Ca-P surface. Only occasionally, intervening fibrous tissue was 
present between the radius defect border and the implant surface. Bone formation had 
penetrated through all scaffolds, but the amount of bone varied. In the newly formed bone 
osteoblasts and osteocytes could be detected.
All empty control defects showed regeneration of the radius and were completely closed 
with new bone tissue. In addition, fusion of ulnar and new radial bone was seen in almost 
all samples.
51
3
Group II (10 mm)
In 9 out of 10 specimens, bone formation had penetrated into and through the porous 
Ca-P implants (Figure 4A-2). However, the amount of bone varied between the various 
specimens. Bone formation was associated with the ingrowth of blood vessels. An 
intervening soft tissue layer was present at radial defect border of three samples and no 
bone ingrowth from this side was observed. Some bone tissue and fibrocartilagenous tissue 
was interposed between the pCa-P implant and ulna. Further examination revealed also 
that two of the scaffolds showed some displacement out of the defect. 
Bone regeneration in the open control defects was similar to the group I defects, but in 
two of the open control defects there was no bone bridging. The rest of the non-filled defects 
(n=7) were completely closed histologically (Figure 4A-1). 
FIGURE 4A-1: 10 mm control defect. Magnification: 1.6x. 
FIGURE 4A-2: 10 mm p Ca-P implant. Magnification: 1.6x. 
FIGURE 4A+B: Histology results after 12 weeks’ implantation time. 
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Group III (15 mm)
The pCa-P cement implants were still in place after 12 weeks of implantation and all 
specimens showed bone formation throughout the Ca-P implant porosity (Figure 4B-2). 
Again, blood vessel ingrowth was observed in these implants. Fibrocartilagenous and 
limited bone tissue had formed in the area between the pCa-P implant and ulna. Further, 
an intervening soft tissue layer at the implant- radial defect border was present in two 
samples. Although bone was still present in the implant porosity of these implants, ingrowth 
did not occur from the edges. Two of the implants were found to be displaced and two of 
them showed fracture lines, without dislocation. 
The sections of the empty control defects showed that seven of these defects were still 
open after 12 weeks. Only in two out of 9, bone bridging was visible histologically, but bone 
formation at the ulnar surface was limited.
FIGURE 4B-1: 15 mm control defects. Magnification: 1.6x. 
FIGURE 4B-2: 15mm p Ca-P implant. Magnification: 1.6x a fracture line is visible (arrows). 
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DiSCUSSioN
This study aimed to assess the bone healing supporting characteristics of porous Ca-P 
cement when implanted in a rabbit segmental defect model. Bone formation into the 
cement porosity was seen in all three defect sizes in which implants were inserted. In view 
of this, the results provide evidence that porous Ca-P cement shows osteoconductive 
properties. A similar observation was done in a previous study dealing with the regeneration 
of large sized cranial defects of rabbits.6,27 In addition, the torque measurements revealed 
that all pCa-P filled defects obtained the same mechanical strength as non-operated radii. 
Further, we have to emphasize that we decided to use the Ca-P cement in a pre-set form in 
order to avoid experimental variation due to differences in implant shape or total amount 
of implant material.
The torque or torsional test is described as a method to measure the strength of bone 
and is preferred to evaluate the mechanical properties of bone associated with fracture 
healing. Therefore, torsional testing is a frequently used technique to evaluate bone healing 
in long bone segmental defect models, because bone fails in torsion at the weakest point 
along the shaft.
It has to be emphasized that there are different approaches to perform a torque test. In 
some studies, separation of the radius or ulna is performed.14,28-31 For example, Cook et al 
created 15 mm defects in the ulna of a rabbit, isolated the ulna carefully from the radius 
and placed the distal ends in an aluminum sleeve.28 As the ulna has a curved shape, the 
ulna had to be mounted eccentrically to keep the axis of the ulnar rotation coaxial with the 
testing device.28 The measured average torsional strength and energy absorption of the 
healed ulna defect was comparable to the intact ulna after 12 weeks’ implantation time. 
Beck et al created 15 mm segmental defects in the rabbit radius and augmented the defects 
with a combination of bone marrow and TGFß1.14 They isolated the radii using bone 
rongeurs when the ulna was fused to the operated radius and thereafter mechanical testing 
was carried out.14 They also removed one centimeter of the distal and proximal radius 
before fixing them into the mechanical testing apparatus. However, it has to be noticed that 
when the distal bone fragments are removed, the torque results can be influenced because 
the angle of rotation changes more when the length of the radius is shorter. Also, Mori et al 
isolated the radius carefully from the ulna of a rabbit and cut it into a 5-cm-long sample.30 
Subsequently, both ends were fixed in a square mold.30 In this 24 week study, no statistically 
significant differences were found between ulnae regenerated by rhBMP-2/PLGA capsules 
and the intact contralateral bones. 
The difficulties that occur when the radius and ulna are separated before mechanical 
testing is especially evident in the study of Sheller et al, who created non-critical sized 
defects in the radii and non-critical sized defects in the ulnae of New Zealand White 
rabbits.29 All ulnae and radii were separated before torsional testing was done. Finally, they 
observed that six out of 16 control bones could not be tested as they were either fractured 
due to the separation process or had no bridging. When 37,5% of the control samples are 
lost, as was the case in Sheller’s experiment, it might be difficult to draw any conclusion. In 
addition, bone formation outside the defect site and bone not spanning the defect might be 
difficult to distinguish during the separation process, which can as well influence the final 
measurements. In agreement with the above mentioned, it will be clear that in the present 
experiment separation of the bones would have influenced the test results because 
histological examination of the samples revealed some bone, but also fibrocartilagenous s 
tissue located in the area between the radius and ulna. Also, bone overgrowth (i.e. 
osseoconduction over the implant surface) is difficult to discern macroscopically. This gives 
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the additional risk of removing too much of the newly formed bone, which results in an 
unreliable measurement.
Similar to the technique as used by Wheeler et al 8, we potted the ulna-radius complex 
in dental plaster and made transcortical incisions as close as possible near the embedding 
of the ulna in the plaster. This was done to eliminate the mechanical contribution of the 
ulna. Nevertheless, it has to be questioned whether this discontinuous ulna segment has 
still no effect on the fracture torque or stiffness of the radius (Figure 5). For example, our 
histological analysis showed that bone and cartilagenous tissue formation had occurred in 
the area between the radius and ulna, which can influence the outcome of the measurements. 
Further, there is always the risk of additional experimental flaws, like variability of the 
transcortical incisions, fracture of the dental plaster and instability of the fixation. 
Due to these limitations of a torsional test, other methods have been suggested to 
measure the strength of newly formed bone in a segmental defect. An alternative approach 
is the use of a compression test, but separation of the ulna and radius is still required in this 
method as a load is applied vertically to the specimen along the longitudinal axis of the 
ulna or radius. Of importance is also that in this test, the angle of the radius and the fixation 
of the bone in the instrument can influence the measurements. Besides compression, a 
bending test can be done, but the disadvantages of this method are that: (1) there are no 
equal loads to all sections of the bone, and (2) the test is relatively insensitive to specimen 
length and orientation.32,33,34 
FIGURE 5: The ulna-radius complex after creation of the transcortical incisions. The discontinuous ulna 
segment can affect the torque because of fusion in the area between radius and ulna. 
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Besides the applied mechanical test method, there are a lot of other variables that can 
influence the outcome of mechanical assays. For example, anatomical differences, which 
cause angular variation between the radius and ulna, can influence the measurements as 
well as the inherent strength of a radius will vary from rabbit to rabbit. Also, the mechanical 
properties of the scaffold material are important, e.g. the use of a mechanically strong 
material is mechanically strong will result in less displacement or impression compared to 
weaker scaffold materials. All these limitations were present in the current study and could 
not be excluded, which can explain the high standard deviation in the measurements as 
well as the lack of a significant difference for the 15 mm open defect.  
To assess the suitability of porous Ca-P cement as a bone substituting material, this 
experiment aimed on the creation of a CSD defect in the radius of New Zealand white 
rabbits. The radiology results showed that two of the 15 mm control defects showed signs of 
spontaneous closure, which was confirmed by the histological analysis. As a consequence, 
the created 15 mm defect cannot convincingly be considered as critical-sized. The size of a 
CSD is known to depend on the breed and age of the used experimental animal model as 
well as the location of the defect. Also the surgical technique, such as the experience and 
skills of the surgeon, the used saline cooling, the way to treat the periosteum (whether it is 
taken away of lifted), and removal or maintenance of the interosseus membrane are of main 
importance. For example, Sheller et al reported that a segmental defect could elicit bone 
formation from the periosteum of the nearby radius when an ulna defect is created.29 
Considering the histological evaluation, a limitation in the study design was that we 
were not able to quantify the amount of bone formation and cement degradation. The 
torqued specimens showed fracturing of the pCa-P implants, which prevented the 
performance of reliable histomorphometrical measurements, while the number of non-
torqued specimens was too limited to allow appropriate statistical analysis. In addition, no 
clear sign of cement degradation was observed in the histological sections, which 
corroborates with our previous study dealing with rabbit cranial defects.27 An explanation 
for this lack of degradation can be the used animal model, as significant degradation of 
Ca-P cement has been reported in studies with different animal species.22,35
 
CoNClUSioNS
Within the limitation of the study design, porous Ca-P cement implants demonstrated 
osteoconductive properties and confirmed to be a suitable scaffold material in a weight 
bearing situation. Nevertheless, the results have to be interpreted with care, as the torque 
testing revealed that several variables can interfere with the study outcome. Also, this study 
confirmed again that a 15 mm radius defect is not a CSD in female New Zealand white 
rabbits of six month of age (weight 2.5-3.5 kg).
Acknowledgement: This study has been supported by the NWO-AGIKO foundation. 
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BONE INDUCTIVE PROPERTIES OF rhBMP-2 LOADED 
POROUS CALCIUM PHOSPHATE CEMENT IMPLANTS IN 
CRANIAL DEFECTS IN RABBITS
iNTRoDUCTioN
The use of autologous bone grafts is considered to be the golden standard for repair 
and reconstruction of bone. To overcome the disadvantages of this technique, such as (1) 
the low availability of transplantable tissue, (2) postoperative morbidity, and (3) lack of 
functional shape of the transplant, several alternatives to autologous bone have been 
investigated. One of these is tissue engineered synthetic bone graft substitute (BGS). In 
this concept, a BGS consists of an osteoconductive scaffold material combined with 
osteogenic cells and/or osteoinductive proteins. 
A lot of prerequisites have been postulated for the ideal scaffold material with regard 
to mechanical properties, biocompatibility, biodegradability, absence of allergic reactions, 
disease transmission, delivery of the osteoinductive factor, gross architecture, shaping, 
clinical handling, and regulatory issues. Nevertheless, none of the currently available 
scaffold materials meets all of the formulated demands.
Calcium phosphate (Ca-P) cements have been studied extensively.1-5 Besides the
clinical advantage that this cement can be injected directly into a bone defect, it shows 
a fast deposition of new bone at the cement surface and is considered to be extremely 
biocompatible.6,7 To enhance tissue ingrowth and degradation rate of the cement, we
have recently developed a method to increase the porosity of the cement by creating 
macropores.8 In an animal study in goats, the degradation rate was shown to increase
up to 80% in ten weeks.9
Osteoinductive proteins play an important role in bone regeneration. These proteins 
belong to the Transforming Growth Factor (TGF)-ß super family. Currently fifteen 
different Bone Morphogenetic Proteins (BMPs) have been identified.10 Various in vitro
and in vivo (rodents, dogs, sheep, humans) studies have been done to establish the 
osteoinductive effect of BMP.11-18 Especially human BMP-2 has been investigated
thoroughly for bone engineering purposes. This homodimeric protein can be produced 
by human recombinant technology since 1988 and consists of two polypeptide chains of 
more than 400 amino acids.16,19 A region with seven cystine amino acids located near
the C-terminus plays a crucial role in the protein function.19 Recent investigations
showed that the so-called cystine knot is located in the core of the complex three 
dimensional structure.20,21 More insights into the primary steps of BMP receptor
activation have been provided with the characterization of two receptor binding epitopes 
for high affinity BMP receptors.20,22 Binding of BMP to cell surface receptors on 
mesenchymal cells activates a BMP signaling cascade that results in gene expression and 
leads to differentiation of the mesenchymal cells into chondrocytes or osteoblasts.21
The role of biomaterials on the osteoinductive activity of BMP is not completely clear. The 
biomaterial itself might directly influence cellular differentiation23 and it might
potentiate the activity of BMP by binding the protein and presenting it to target cells 
in a “bound” form.24,25 On the other hand, slowly released BMP may provide a
physiological concentration of free protein in the vicinity of the implant, what may attract 
target cells to the implant-site by chemotaxis.26 The ideal retention/release rates for
growth factors have not been established yet. 
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Although in several studies the combination of growth factors with calcium phosphate 
ceramics, like hydroxyapatite and tricalciumphosphate, has been reported,18,27-33 to our 
knowledge only a few studies have been carried out with Ca-P cement and osteoinductive 
proteins.34-38 The Ca-P cements used in these studies did not have a macroporous
structure and growth factors were mostly added to the cement before setting. 
To our knowledge, this is the first study with macroporous Ca-P cement and 
rhBMP-2. We hypothesize that: 1) Porous Ca-P cement is an appropriate candidate 
scaffold material for bone engineering purposes. 2) Bone formation in porous Ca-P 
cement can be enhanced by lyophilization of rhBMP-2 on the scaffold surface. 
3) Porous rhBMP-2 loaded Ca-P cement discs show degradation after implantation 
in cranial defects in rabbits for ten weeks.
MaTERialS aND METHoDS
Porous calcium phosphate cement implants
Thirty-six disc-shaped porous calcium phosphate (Ca-P) cement implants were 
prepared by a CO2 induction technique as previously described.8 The discs were madeout of Calcibon® (Biomet Merck, Darmstadt, Germany). This cement consists of a
mixture of 62.5wt% tricalcium phosphate (α-TCP), 26.8wt% dicalcium phosphate 
anhydrous (DCPA), 8.9wt% calcium carbonate (CaCO3) and 1.8wt% hydroxyapatite(Hap). An aqueous solution of Na2HPO4 (2wt%) was used as the liquid component.To generate macroporosity of the scaffold, NaHCO3 was added for production of CO2 gas in the cement. After mixing, the cement was immediately injected in a cylindrical mould 
of 2.7 mm height and 8.0 mm diameter. The discs were air dried in a furnace at 50°C 
for 1 h. Thereafter, the surface of the discs was carefully ground with fine sand-paper 
to ensure a standardized height of 2.7 mm. Finally, the discs were removed from the 
moulds and sterilized by autoclaving for 15 min at 121°C. Average weight was 108 ±7 mg/
disc. The total porosity of the discs was 75% as was calculated with the formula: 
porosity (%) = 100 × {1-(disc weight/ [cement density × disc volume])}. Histomorphometrical 
analysis of the discs before implantation revealed that the macroporosity was 36%. In a 
previously published paper, it was shown that the microporosity (pores < 1 μm) of this 
cement is 39%.8
absorbable collagen sponge implants
As positive reference material for administration of rhBMP-2, sterile absorbable 
collagen sponge (ACS) was used as provided by Dr. D.W.R. Hall (Yamanouchi 
Europe BV, Leiderdorp, The Netherlands). Under sterile conditions the ACS sheets 
(thickness 3.5 mm) were moistened with H2O to induce the common shrinkage of the material and the sheets were lyophilized subsequently. Thereafter, discs were punched 
out of the lyophilized sheets with sterile 8 mm biopsy punches (Stiefel Laboratories BV, 
Veendam, The Netherlands) under sterile conditions. 
rhbMP-2 loading
Eighteen porous Ca-P cement implants were loaded with rhBMP-2 (Yamanouchi 
Europe BV, Leiderdorp, The Netherlands) one day prior to implantation. Thereafter, 
the Ca-P discs were placed in a sterile Eppendorf ® tube under sterile conditions and 25 μL 
of diluted rhBMP-2 (0.2 mg/ml PBS/BSA[0.1%]) was added to each side of the 
implant to achieve a total dose of 10 μg per implant. The specimens were lyophilized 
and stored at 4°C until implantation.
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Eighteen ACS discs were loaded with rhBMP-2 on the day of implantation as 
prescribed by the provider. To achieve a total dose of 10 μg rhBMP-2 per implant with 
a soak-load of 30%, 50 μL of the diluted rhBMP-2 solution (0.2 mg/ml PBS/BSA[0.1%]) 
was pipetted carefully onto the discs of ACS. The ACS discs were allowed to soak-load 
for minimally 15 min before being inserted into the cranial defects. Care was taken not 
to squeeze the discs.
Surgical procedure for cranial implants:
Fifty-four healthy skeletally mature female New Zealand White rabbits with a 
weight between 2.8 - 3.2 kg were used as experimental animals. National guidelines 
for the care and use of laboratory animals were observed. 
Surgery was performed under general inhalation anesthesia. The anesthesia was 
induced by an intravenous injection of Hypnorm® (0.315 mg/ml fentanyl citrate and
10 mg/ml fluanisone) and atropine, while maintained by a mixture of nitrous oxide, 
isoflurane, and oxygen through a constant volume ventilator. To reduce the peri-operative 
infection risk, the rabbits received antibiotic prophylaxis [Baytril® 2.5% (Enrofloxacin), 
5-10 mg/kg].
For the insertion of the implants, the animals were immobilized in ventral position. 
The skull was shaved, washed and disinfected with povidone-iodine. A longitudinal 
incision was made down to the periosteum from the nasal bone to the occipital 
protuberance. Subsequently, a midline incision was made in the periosteum. The 
periosteum was undermined and lifted off the parietal skull. The defect was drilled in 
the parietal calvarial bone with a dental trephine burr (ACE Dental Implant System, 
Brockton, MA, USA) with an outer diameter of 8.0 mm and continuous internal and 
external cooling with physiologic saline. Care was taken to make a full thickness defect 
without damaging the underlying dura. Following insertion of the implants (Fig. 1A and 
1B), the periosteum was closed using non-resorbable Prolene® 4-0 sutures. Finally, the skin 
was closed intracutaneously using resorbable Vicryl® 4-0 suture material. Implantation 
periods were two and ten weeks. At the end of each implantation period, euthanasia was 
performed with an overdose of Nembutal® (pentobarbital). 
FIGURE 1A: rhBMP-2 loaded ACS implant inserted in cranial defect.
FIGURE 1B: Porous Ca-P cement implant inserted in cranial defect (left) and empty defect (right).
A B
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In this way, a total of fifty-four implants were placed into the fifty-four rabbit 
skulls: eighteen rhBMP-2 loaded Ca-P cement implants, eighteen unloaded Ca-P 
cement implants and eighteen rhBMP-2 loaded ACS implants (n=9 for each implant 
and time period). In the group of rabbits that received an unloaded Ca-P cement 
implant, an additional defect was drilled in the contralateral parietal bone, which was 
left open and served as control (empty defect). In this group, no rhBMP-2 was 
administered. Therefore, there was no cross-over effect of rhBMP-2.
Sequential quadruple fluorochrome labeling, i.e. tetracycline (yellow), alizerin-
complexon (red), calcein (green) and tetracycline (yellow), was performed in four 
rabbits of each group at respectively one, three, seven and nine weeks postoperatively. All 
labels were administered subcutaneously at 25 mg/kg body weight. Parallel to this study, 
a separate study was performed in the same animals where identical experimental 
groups were implanted subcutaneously.
implant retrieval and histological preparations.
Directly after euthanasia, implants with the surrounding tissues were retrieved and 
fixed in 4% phosphate-buffered formaldehyde solution (pH=7.4). Subsequently, the 
tissue blocks were dehydrated in ethanol and embedded in methylmethacrylate. 
Following polymerization undecalcified 10-µm-thick sections were prepared in a 
transverse direction to the implant’s axis using a modified sawing microtome technique.39 
At least three sections of each implant were stained with methylene blue/basic fuchsin 
and examined with a light microscope. Two additional unstained 30-µm-thick sections of 
the fluorochrome-labeled specimens were prepared for reflectant fluorescence microscopy. 
Histological and histomorphometrical evaluation
A light microscope (Leica Microsystems AG, Wetzlar, Germany) was used for 
histological evaluation. This evaluation consisted of a morphological description of three 
sections per implant. 
Further, all sections that contained Ca-P cement implants were used for 
histomorphometrical evaluation using computer based image analysis techniques (Leica® 
Qwin Pro-image analysis system, Wetzlar, Germany). Digital analysis determined 
the following parameters: 
1. The surface of the area within the defect edges and the thickness of the implant, which 
was called region of interest (ROI). 
2. Cement surface area [%], indicative for the macroporosity. 
3. Total bone area in Ca-P specimens [%], defined as the index of the surface area of bone 
and the ROI. This parameter was subdivided in: A. Bone inside the cement (BIC), defined 
as bone formed within the implant edges. B. Bone outside the cement (BOC) defined 
as newly formed bone deposited outside the implant at either skin- or cerebral side.
4. Pore fill [%], defined as the index of BIC and the surface area of macropores. 
The results are based on the average of the separate measurements of three sections 
per implant. We have to emphasize that no histomorphometrical measurements were 
done for the ACS implants. A quantitative comparison of parameters for this group 
would be unreliable since no proper ROI, in terms of implant thickness and area, could be 
defined for the spongy ACS. 
A reflectant fluorescence microscope equipped with an excitation filter of 470-490 nm 
(Leica Microsystems AG, Wetzlar, Germany) was used for fluorescent microscopical 
assessment. 
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Statistical analysis
All measurements of rhBMP-2 loaded and unloaded porous Ca-P cement implants were 
statistically evaluated with GraphPad® Instat 3.05 software (GraphPad Software Inc, San 
Diego, CA, USA), using an unpaired T-test with Welch correction. 
RESUlTS
Experimental animals
During the experiment, all fifty-four rabbits remained in good health and did not 
show any wound complications. At the end of the two implantation periods, a total of fifty-
four implants and eighteen empty control defects could be retrieved. At retrieval, the 
implants were all covered by periosteum. No inflammatory signs or adverse tissue 
reaction could be observed. Bone formation could be seen macroscopically in most of 
the specimens.
light microscopy
Light microscopic analysis of the sections revealed various amounts of bone 
formation between implants, groups and time periods. In all sections, the original defect 
edge was still visible. Little or no inflammatory multinucleated cells were observed on 
the cement surface. Representative sections are depicted in Figure 2.
FIGURE 2: 
Overview of 
representative 
sections of implants 
and empty defects 
after two and ten 
weeks (original 
magnification 2.5x).
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Two weeks specimens
Two weeks postoperatively, none of the empty defects was closed completely. Primary 
bone ingrowth from the defect edge to the defect center covered about half of the 
defect diameter. In the ACS group, all defects were completely closed after two weeks of 
implantation. The new-formed primary bone was characterized by the presence of 
osteoblasts, osteocytes and small blood vessels and had a structure, comparable with 
the new bone formation in the empty defects. Microscopically, no collagen left from 
the ACS material could be observed. The newly formed bone layer was thinner than 
the originally inserted ACS material and thinner than the surrounding skull bone in all 
sections. 
Light microscopy showed that the macropores in the Ca-P cement implants were 
irregularly formed and had a channel-like rather than a spherical structure. In three 
unloaded Ca-P cement implants, some fracturing of the scaffolds occurred. In these 
sections, fracture lines in the Ca-P cement and loose Ca-P fragments were observed. 
However, the outline of these discs was not affected. All other implants had maintained 
their integrity. Fibrous encapsulation of the Ca-P cement implants was not observed. Bone 
ingrowth from the skull bone into the macropores of the cement was present in all 
implants. Also, direct bone contact with the cement and layers of osteoblast-like cells 
were observed in all sections. At the interface, no inflammatory cells or fibrous tissue 
were present between bone and cement. Further inside the implant, macropores were 
filled with loose connective tissue and blood vessels. Remarkably, all rhBMP-2 loaded 
Ca-P implants were surrounded by a thin layer of primary bone outside the cement at the 
cerebral side of the implant, the skin side or both sides. This callus-like tissue was 
characterized by the frequent absence of contact between bone and cement. In eight out of 
nine implants, the bone outside the cement covered the defect completely. A very limited 
formation of bone outside the cement was also observed in three of the unloaded Ca-P 
cement implants. 
Ten weeks specimens
Ten weeks postoperatively, average bone ingrowth in the empty defects covered about 
75% of the defect diameter. One of the empty defects was closed completely by a thin 
layer of new trabecular bone. In the ACS group, all defects were completely closed. The 
primary bone of the two weeks ACS implants was now replaced by a more cortical-like 
structure. Occasionally, the newly formed bone was difficult to discern from the 
original skull bone. Further, we noticed that in four of the nine specimens the newly 
deposited bone was not formed according the original skull contour and lacked the finally 
required shape. Microscopically, the ACS appeared to have degraded completely. 
All of the Ca-P cement scaffolds were intact and had maintained their integrity. Bone 
bridging between the Ca-P implant and skull occurred in all specimens. Bone ingrowth 
in both the rhBMP-2 loaded and unloaded Ca-P cement scaffolds had increased 
dramatically compared to the two weeks implants. Complete closure of the defect was 
observed in all rhBMP-2 loaded specimens and in seven unloaded specimens. The deposited 
bone had a more lamellar appearance than after two weeks of implantation. Bone formation 
in the cement porosity was characterized by the presence of osteoblast- as well as osteocyte-
like cells embedded in a mineralized matrix (Fig. 3). Also, bone remodeling and bone 
marrow-like tissue were observed. Osteoclast-like cells and foreign body giant cells were 
noticed occasionally. Formation of bone outside the Ca-P cement was present in eight of 
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the nine rhBMP-2 loaded Ca-P scaffolds. Unlike the two weeks sections, the bone outside 
the cement was frequently in direct contact with the Ca-P cement. In the unloaded group, 
formation of bone outside the scaffold was very limited in four of the nine scaffolds. 
Here, direct bone- Ca-P cement contact existed also. Finally, in both the rhBMP-2 
loaded and non-loaded Ca-P cements implants no clear indication for cement degradation 
was observed.
fluorescence microscopy
Results of fluorescence microscopy are depicted in Figure 4. Tetracycline labels, 
that were administered one and nine weeks post-operatively, were scarcely observed. 
Analysis of the fluorescence labels revealed that formation of bone started at the cement 
surface and proceeded into the macropores.  
FIGURE 3:
Light microscopic aspect of bone 
formation in the center of a rhBMP-2 
loaded Ca-P cement scaffold after ten 
weeks of implantation. Bone formation 
is characterized by the presence of 
osteocyte-like cells (OC) embedded in 
the matrix and the layer of cubical 
osteoblast-like cells (OB) at the matrix 
surface. Bone marrow-like tissue (BM) 
is observed in the macropores. Original 
magnification 10x. Bar represents 100 µm.
FIGURE 4:
Fluorescence microscopy of bone 
formation in the center of a rhBMP-2 
loaded Ca-P cement scaffold. Formation 
of bone started at the cement surface 
and proceeded into the macropore. 
A= alizerine complexon label (red), 
administered after three weeks of 
implantation. C= calcein label (green), 
administered after seven weeks of 
implantation. T= tetracycline label 
(yellow), administered after nine weeks of 
implantation. Original magnification 20x. 
Bar represents 50 µm.
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Histomorphometry
The results of the histomorphometrical analysis of the Ca-P specimens are shown in 
Figures 5 and 6.
Measurement of cement surface before implantation revealed a cement/ROI ratio of 
63.6 ±0.3%, indicative for a macroporosity of the scaffold of 36.4 ±0.3%. After two and 
ten weeks of implantation, the macroporosity was not significantly changed (p>0.05). 
In the histomorphometrical analysis, we discerned total bone formation in bone 
inside the cement (BIC) and bone outside the cement (BOC). In the rhBMP-2 loaded 
group, total bone surface area increased from 8.9 ±7.1% (BIC: 3.2 ±1.9%; BOC: 5.7 ±5.3%) 
after two weeks to 27.4 ±6.2% (BIC: 19.5 ±3.6%; BOC: 7.9 ±3.3%) after ten weeks. In the 
unloaded group, total bone surface area increased from 3.2 ±1.9% (BIC: 2.4 ±1.2%; BOC: 
0.8 ±1.1%) after two weeks to 16.6 ±5.1% (BIC: 14.2 ±4.4%; BOC: 2.4 ±1.6%) after ten 
weeks. Statistical testing revealed that these increases were significant (p< 0.0001) for 
both groups. Comparison between loaded and unloaded groups showed that total bone 
surface area was significantly higher in the rhBMP-2 loaded group after two weeks 
(p< 0.05) and after ten weeks (p< 0.005). 
After two weeks of implantation, pore fill in the rhBMP-2 group (9.3 ±3.7%) was not 
significantly different from the unloaded group (8.3 ±4.0%). After ten weeks, pore fill 
was significantly higher (p< 0.05) in the rhBMP-2 group (53.0 ±5.4 vs. 43.1 ±10.4).
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FIGURE 5:
Total bone surface in porous Ca-P cement scaffolds, expressed as the index of the surface area occupied by 
bone and the region of interest (ROI). Total bone formation is subdivided in bone inside the Ca-P cement 
(BIC) and bone outside the Ca-P cement (BOC). Error bars represent means ± standard deviation for 
n=9. * = p< 0.05 ** = p< 0.005.
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DiSCUSSioN
This study focuses on the osteoinductive properties of rhBMP-2 loaded porous Ca-P 
cement in cranial defects in rabbits. The critical size of cranial defects in rabbits has 
been reported to measure 15 mm in diameter for implantation periods up to twenty-four 
weeks.40,41 This corroborates with our findings in previous research, which showed
that 7.3 mm cranial defects are non-critical size defects for implantation periods of eight 
weeks.42 In the current study, one open defect had closed completely after ten
weeks and the remaining eight defects showed a tendency to complete closure. However, 
it should be noticed that we did not intend to create a critical size defect in the 
current study. Our aim was to investigate whether lyophilized rhBMP-2 on a porous 
Ca-P cement scaffold surface stimulated bone formation. 
rhBMP-2 loaded ACS was used in this study as positive reference material for 
rhBMP-2 bone induction. Unloaded ACS was not included since the carrier material 
was not under investigation in this study, and has been investigated thoroughly.35,43-46
The loaded ACS proved to be a powerful osteoinductive positive reference, as bone 
bridging was observed in all ACS filled defects after two weeks of implantation. 
Unfortunately, histomorphometrical comparison of ACS and Ca-P cement implants was 
impossible due to the indefinable region of interest (ROI) in the ACS group. We 
underline the importance of the ROI for histomorphometry and we refrain from 
quantitative comparison if this parameter is insecure. However, the qualitative 
histological analysis revealed that in four of the ACS implants, the new deposited 
bone showed some variety in contour and did not match the desired shape. We presume 
that this is due to the flaccid aspect of the collagen sponge. Despite the excellent 
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osteoinductive properties, this lack of shape maintenance is a drawback of the rhBMP-2 
loaded ACS as a scaffold material for bone engineering.
The complete closure of all defects filled with unloaded Ca-P cement indicates 
that porous Ca-P cement did not hamper the physiologic bone healing response. 
Biocompatibility of porous Ca-P cement was confirmed by histological analysis of 
the sections. Formation of fibrous capsule around the implant was observed in none of 
the sections. In agreement with previous studies, few multinucleated inflammatory 
cells were seen on the cement surface.9 Loose connective tissue and blood vessel
ingrowth occurred in all macropores throughout the scaffolds. The macropores in this 
ceramic can thus be regarded as completely interconnected.
Fluorescence microscopy revealed that formation of bone started at the cement 
surface and proceeded into the macropores. This observation agrees with previously 
described bone deposition in porous ceramics47 and emphasizes again the beneficial
effect, which Ca-P ceramics of a specific geometry and composition can have on bone 
healing. 
The histomorphometrical analysis showed that after ten weeks of implantation pore 
fill and total bone surface area were significantly higher in the rhBMP-2 loaded 
Ca-P cement scaffolds than in the unloaded scaffolds. This confirms that administration 
of rhBMP-2 can indeed enhance the formation of bone in porous Ca-P cement scaffolds. 
As the defects created in the current study were non-critical size and bone formation 
also occurred without administration of growth factor, we assume that the significance 
of bone formation induced by rhBMP-2 will increase in clinically more relevant (critical 
size) defects. Nevertheless, we have to emphasize that the unloaded Ca-P cement scaffolds 
also supported a fair amount of bone formation inside the cement porosity. We suggest 
that this is due to the osteoconductive qualities of the macroporous Ca-P cement. 
Perhaps the most striking difference between the loaded and unloaded implants 
was the early callus-like bone formation outside the cement as occurred in all of the 
rhBMP-2 loaded two weeks implants. To determine whether this bone formation was 
induced by a relatively high concentration of growth factor in the surrounding tissues, 
we assessed the in vitro rhBMP-2 release profile from Ca-P cement with 125I labeled 
rhBMP-2 in an additional study according to previously described methods (fig. 7).48
The results showed that our Ca-P cement scaffolds showed no initial burst release. 
Instead, there was a very limited release of the loaded rhBMP-2 of accumulatively 
9.7 ±0.9% after 28 days. In other studies, limited release of growth factors from Ca-P 
cement in vitro has been reported also.37,49 It is known from column chromatography 
separation techniques, that ceramics exhibit a high binding affinity for proteins. 
However, the exact binding mechanism of rhBMP-2 on a ceramic surface is not known to 
our knowledge. Therefore, it remains unclear how the protein is attached to the 
ceramic surface, and whether the receptor binding epitopes maintain their accessibility. 
Binding of BMP on a biomaterial has even been suggested to potentiate the activity of 
the protein.24 Unfortunately, no data are available on the activity of “bound” rhBMP-2
on ceramic surface. Evidently, the limited release of rhBMP-2 in vitro does not explain 
the formation of bone outside the scaffold, unless the early physiologic callus 
formation is very sensitive to induction by rhBMP-2. On the other hand, we noticed 
that Li et al reported slow release of rhBMP-2 from a Ca-P cement in vitro, whereas in 
vivo release was significantly faster.37 Therefore, the in vitro release profile as determined
in the current study can still be an underestimation of the in vivo release and the 
subsequent concentration of growth factor in the surrounding tissues.
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In a previous study, we have demonstrated that degradation of porous Ca-P cement 
can reach up to 80% after ten weeks.9 In that study, a trabecular condylar defect in goats was 
filled with a Ca-P cylinder. In contrast, in the current animal model no degradation 
of the cement was observed after ten weeks of implantation. Initial bone-implant contact 
surface area was relatively large in the cylinder shaped defect in the goat study and relatively 
small in the current study. Therefore, in the current study there was less initial bone ingrowth 
and a longer time was needed before the cement was completely surrounded by bone. 
Consequently, the manifestation of osteoclasts and degradation of the Ca-P cement might 
occur later. This confirms that the degradation rate of porous Ca-P cement is influenced by 
various factors such as species, implantation site and implant geometry.  
CoNClUSioNS
We conclude that porous Ca-P cement is an appropriate candidate scaffold material 
for bone engineering purposes. This material reveals excellent osteoconductive 
properties and maintains its shape and stability during the formation of new bone. 
Bone formation in porous Ca-P cement scaffolds can be enhanced by lyophilization of 
rhBMP-2 on the scaffolds. Degradation of porous Ca-P cement is species-, implantation 
site- and implant dimension-specific.
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BONE INDUCTIVE PROPERTIES OF rhBMP-2 LOADED 
POROUS CALCIUM PHOSPHATE CEMENT IMPLANTS 
INSERTED AT AN ECTOPIC SITE IN RABBITS
iNTRoDUCTioN
Bone tissue is one of the most frequently used tissues for transplantation. The vast 
demand for bone is due to various reasons, i.e. to fill defects caused by trauma or tumor 
resection, reconstruction of congenital malformation and age related decrease of bone 
mass. Autogenous bone is the treatment-of-choice to restore and augment osseous 
structures. Unfortunately, insufficient autogenous bone is available for reconstruction in 
many cases. 
Furthermore, autografting is associated with donor-site morbidity. Many complications 
like infection, pain, loss of sensibility and hematoma have been described.1 Therefore, 
several alternatives to autogenous bone have been investigated. One of these are the so 
called synthetic Bone Graft Substitutes (BGSs).2-5 A BGS could be engineered directly at 
the recipient site (orthotopically) or, depending on medical implications such as radiation 
therapy or unfavorable local physical conditions, it could be prefabricated ectopically in 
subcutaneous or intramuscular pockets before being transplanted to the recipient site. 
Calcium phosphate (Ca-P) cement is one of the materials currently under investigation 
for its potential as BGS.6-9 An advantage of cement-like Ca-P materials is that they can be 
injected directly into a bone defect and can be shaped and molded to fit the required shape. 
Further, Ca-P cements are considered to be extremely biocompatible and show fast 
deposition of new bone at their surface.10,11 Recently, a method has been developed
within our laboratory to increase the porosity of the cement by creating macropores.12
In this way, the degradation rate and tissue ingrowth of the cement were enhanced.13 
Besides the scaffold material, another important component in bone regeneration are 
osteoinductive factors like Bone Morphogenetic Protein (e.g. BMP-2). BMP’s play an 
important regulatory role in many steps in bone morphogenesis like chemotaxis, 
differentiation as well as mitosis of cartilage and bone producing cells.14 At this moment 15 
different kinds of BMPs are known,15 which belong to the Transforming Growth Factor 
(TGF)-β gene super family. Research especially focuses on the bone regenerating 
properties of BMP-2 and BMP-7.14,16-19 Both factors are available in large quantities
by human recombinant technology. BMP-2 also showed osteogenic activity at 
intramuscular20,21 and subcutaneous sites.22-24
Osteoinductive proteins require an appropriate carrier material as delivery vehicle.25 
However, the role of biomaterials on the osteoinductive activity of BMP is not completely 
clear. A material itself might potentiate the activity of BMP by binding the protein and 
presenting it to target cells in a “bound” form.26,27 For several biomaterials, a correlation 
between growth factor retention and osteoinductivity has been reported.28 On the other 
hand, slowly released BMP may provide a physiological concentration of free protein in the 
vicinity of the implant, what may attract target cells to the implant-site by chemotaxis.29 
The optimal retention/release rates for growth factors and their carriers have not been 
established yet. 
In the present study, we hypothesized that rhBMP-2 loaded porous Ca-P cement can 
induce bone in an ectopic site. rhBMP-2 loaded as well as unloaded pre-set porous Ca-P 
cement discs were implanted subcutaneously in the rabbit model and compared with the 
current standard for rhBMP-2 delivery, absorbable collagen sponge (ACS). 
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Porous calcium phosphate cement implants
In total, 36 disc-shaped porous calcium phosphate (Ca-P) cement implants were created 
by the CO2 induction technique.12 The implants were made out of Calcibon® (Biomet Merck, Darmstadt, Germany). This cement consists of a mixture of 62.5wt% tricalcium 
phosphate (α-TCP), 26.8wt% dicalcium phosphate anhydrous (DCPA), 8.9wt% calcium 
carbonate (CaCO3 ) and 1.8wt% hydroxyapatite (Hap).Hundred-twenty μl of an aqueous Na2HPO4 (2% in weight) solution was added to the cement, which was placed in a syringe. The syringe was closed with an injection plunger 
and fixed in a mixing apparatus (Silamat® Vivadent, Schaan, Liechtenstein). Thereafter, 
150μl NaH2PO4 (8%) was added in order to create gas bubbles inside the material and to generate macroporosity. The newly formed cement was injected immediately into a 
cylindrical mold to ensure a standardized shape of the implants (discs of 2.7 mm height 
and 8.0 mm diameter, weight 0.11gr/ disc). The samples were placed into an oven at 
50°C for one hour. Afterwards, the surface of the discs was sandpapered to ensure a 
standardized height of 2.7 mm. Finally, the discs were air dried and sterilized by 
autoclaving for 15 minutes at 121°C. 
The average weight of the discs was 108 ± 7 mg. Channel –like macropores varying 
from 100µm to more than 1000µm in length could be detected. Histomorphometrical 
analysis of the discs before implantation showed that the volumetric macroporosity was 
36%. Previously, the microporosity (pores<1 µm) of this cement was shown to be 39%.12
absorbable Collagen Sponge (aCS) implants
Sterile Absorbable Collagen Sponge (ACS) loaded with rhBMP-2, was used as a 
reference material (provided by Yamanouchi Europe BV). Under sterile conditions, discs 
were punched out of lyophilized ACS sheets with 8 mm biopsy punches (Stiefel 
Laboratories BV, Veendam, The Netherlands). Prior to this procedure, the material was 
moistened with H2O under sterile conditions to induce common shrinkage of the material. 
rhbMP-2 loading
The stock solutions of rhBMP-2 (1 mg/ml) were stored frozen at -20°C before use. This 
solution was thawed slowly to refrigeration temperature and was diluted with 4000 μL 
buffer to give a total volume of 5000 μL (rhBMP-2 concentration 0.2 mg/ml). The dilution 
buffer (pH 7.2) for both the Ca-P implants and the ACS implants was PBS/ BSA (0.1%). 
One day before implantation, eighteen calcium phosphate implants were loaded with 
this rhBMP-2 concentration. Twenty-five μL of diluted rhBMP-2 (0.2 mg/ml) was 
administered to each side of the sterile porous Ca-P implants, which were placed in a sterile 
Eppendorf® tube. In this way, a total dose of 10 μg per implant was achieved. Thereafter,
the specimens were lyophilized and stored at 4°C until surgery took place.
In all, fifty μL of the diluted rhBMP-2 solution (0.2 mg/ml) was pipetted carefully 
onto the 8 mm diameter cylindrical pieces of the ACS. In this way, 10 μg of rhBMP was 
present per implant (30% soak-load). The ACS discs were allowed to soak-load for 
minimally 15 minutes before they were implanted subcutaneously. Care was taken not to 
squeeze the discs to prevent the loss of growth factor.
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Surgical procedure 
Fifty-four female New Zealand White rabbits, each weighing 2.8 –3.2 kg, were used 
(“De Vaan” farm, Bergharen, The Netherlands). National guidelines for the care and use 
of laboratory animals were observed. The animals were divided into three groups of 18 
animals (Table 1). Each animal received one subcutaneous implant to prevent cross-over 
effects of rhBMP-2.
Group
No. of 
rabbits implant
Sacrifice of rabbits
2 weeks 10 weeks 
I 18 Porous Ca-P cement 9 9
II 18 Porous Ca-P cement 
+ rhBMP-2
9 9 
III 18 ACS + rhBMP-2 9 9
TABLE 1: Implantation scheme.
Surgery was performed under general inhalation anesthesia and sterile conditions. The 
rabbits received antibiotic prophylaxis (Baytril (2.5% Enrofloxacin), 5-10 mg/kg) before 
surgery. The anesthesia was initiated by an intramuscular injection of 0.5 ml/kg Hypnorm® 
(0.315 mg/ml fentanyl citrate and 10 mg/ml fluanisone) and 0.25 mg atropine. Thereafter, 
the rabbits were intubated and connected to an inhalation ventilator with a constant volume 
of a mixture of nitrous oxide, isoflurane, and oxygen.  
Before the insertion of the subcutaneous implants, each animal was immobilized in the 
ventral position and mid dorsum, the skin was shaved and marked with a small tattoo to 
indicate the implantation site. Subsequently, the skin was washed and disinfected with 
povidone-iodine. Paravertebral, at one side of the spinal column, a longitudinal incision of 
about 1.5 cm was made through the full thickness of the skin. Subsequently, a subcutaneous 
pocket towards the tattoo was created by blunt dissection with a pair of scissors. The implant 
then was inserted in this pocket close to the tattoo. Finally, the skin was closed 
intracutaneously using resorbable Vicryl® 4-0 suture material. A total of 54 implants were 
inserted this way.
Two weeks after implantation, nine animals of each group were euthanized by an 
overdose of Nembutal®. The remaining nine rabbits were euthanized after ten weeks of 
implantation.
At the time of euthanasia the implants with surrounding tissue were retrieved for 
histological analysis. Parallel to this study, a separate study was performed in the same 
animals where identical experimental groups were implanted in the rabbit’s skull.
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fluorochrome labeling
Twelve rabbits of the ten week implantation period (four of each group) received in vivo 
fluorochromes that adsorb to bone mineral during the time they are present in the blood 
circulation. Four markers were administered subcutaneously at timed intervals (1, 3, 7 and 
9 weeks) to deposit at the mineralizing surface of the bone (Table 2). 
Postoperative 
administration 
(weeks)
fluorochrome 
 
Colour 
 
Dose 
 
1 Tetracycline Yellow 25 mg/Kg sc
3 Alizerin-Complexon Red 25 mg/Kg sc
7 Calcein Green 25 mg/Kg sc
9 Tetracycline Yellow 25 mg/Kg sc
TABLE 2: Scheme for administration of fluorochromes to 12 rabbits (four of each group).
Histological preparations
Directly after retrieval, specimens were fixed in 4% buffered formalin solution, 
dehydrated in a graded series of alcohol and embedded in methylmethacrylate (MMA). 
After polymerisation, non-decalcified thin (10 µm) transverse sections of the implant were 
prepared (at least three of each implant) using a modified sawing microtome technique.30 
Methylene blue and basic fuchsin were used for staining the sections. Two extra unstained 
slides (10 µm) were made of the specimens where fluorochrome labeling analysis was 
indicated. 
Histological and histomorphometrical evaluation
The histological evaluation consisted of a concise description of the observed specimens 
and a histomorphometrical analysis of the tissue response using a light microscope (Leica 
Microsystems AG, Wetzlar, Germany). The Leica® Qwin Pro-image analysis system 
(Wetzlar, Germany) was used for the computer based image analysis techniques 
(histomorphometrical evaluation). A reflectant fluorescence microscope equipped with an 
excitation filter of 470-490 nm (Leica Microsystems AG, Wetzlar, Germany) was used for 
the fluorochrome labeling analysis.
All Ca-P cement scaffolds were digitally analyzed. The quantitative measurements were 
performed for all three digitalized sections per implant. Results were based on the average 
of these measurements. ACS implants were not evaluated with this method, because no 
ACS residue or subsequent bone formation could be retrieved after two and ten weeks of 
implantation (see also Results section). 
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The following parameters were assessed for histomorphometrical analysis:
•	 The surface of the area where the implant is inserted, which is called the region of 
interest (ROI).
•	 The bone surface area and the cement surface area (expressed as a percentage of the 
ROI). The cement surface area included microporosity of the cement, since pores 
smaller than 1 µm could not be distinguished histomorphometrically from cement 
particles.
•	 The (macro)pore surface area (%), calculated from the ROI minus the cement surface 
area and bone surface area. 
•	 Pore fill by bone (%), expressed as percentage of pore surface area occupied by bone.
Statistical analysis
Data for all parameters of the of rhBMP-2 loaded and unloaded porous Ca-P cement 
implants were compared among and within groups using an unpaired T-test with Welch 
correction. All statistical analyses were performed with GraphPad® Instat 3.05 software 
(GraphPad Software Inc, San Diego, CA, USA). Differences were considered significant 
at p-values less than 0.05.
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RESUlTS
Experimental animals
In this study, all 54 animals survived the procedure without any signs of disease or 
wound complications. Thirty-six porous Ca-P implants (group I and II) could be retrieved. 
At retrieval, no inflammatory signs or adverse tissue reaction could be observed. All 
implants were surrounded by a thin fibrous capsule.
On the contrary, none of the ACS implants (group III) could be detected and even after 
microscopical evaluation of the area surrounding the tattoo, no ACS residue or signs of 
bone formation were observed. 
light microscopy
Two weeks specimens
Analysis revealed that all Ca-P cement implants had maintained their shape. A thin 
fibrous capsule surrounded the implants. Ingrowth of blood vessels and loose connective 
tissue were present in all macropores throughout the scaffolds. Little or no inflammatory 
cells could be observed at the cement surface. None of the porous Ca-P implants (group I 
and II) showed bone or cartilage formation after two weeks (figure 1A and 1B).
Ten weeks specimens
Ten weeks postoperatively, all Ca-P implants had maintained their shape. The fibrous 
capsule around the discs had a more mature appearance and blood vessel ingrowth was 
more prominent than in the two weeks sections. Bone formation was present in the 
rhBMP-2 loaded group. Bone formation in this group was characterized by the presence of 
osteoblasts and osteocyte-like cells embedded in the matrix (figure 2A, 2B and 3). The 
newly formed bone had a lamellar appearance. Bone remodeling was seen in some sections. 
Bone formation was diffusely spread throughout the macropores of the whole implant. 
Formation of cartilage or bone outside the cement was not observed in any of the Ca-P 
cement scaffolds. 
FIGURE 1A+B:
Light microscopical aspect of the subcutaneous porous CaP+rhBMP-2 implant after 2 weeks. There are no 
signs of bone formation yet (original magnification 1.6x respectively 10x).
1.6x 10x
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FIGURE 2A+B:
Light microscopical aspect of the subcutaneous porous Ca-P +rhBMP-2 implant after 10 weeks of 
implantation. Bone formation is to be seen in the cement scaffolds (original magnification 1.6x respectively 10x).
FIGURE 3:
Light microscopical aspect of the subcutaneous porous Ca-P +rhBMP-2 implant after 10 weeks of 
implantation. Direct apposition of bone on the Ca-P cement surface is observed. OC= osteocyte; 
OB= osteoblast (original magnification 20x).
10x1.6x
PORE
←
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BONE
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CEMENT
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Fluorescence microscopy
The first yellow Tetracycline label and the red Alizerin-Complexon label, administered 
after one and three weeks respectively, were not detected. On the other hand, the green 
Calcein label and the second yellow Tetracycline label, indicative for bone formation after 
seven and nine weeks, were clearly visible in the bone formation in the rhBMP-2 loaded 
Ca-P cement implants (figure 4).
 
Histomorphometry
Histomorphometrical results are summarized in table 3. As previously described, bone 
formation was only present in the ten weeks rhBMP-2 group. In this group, total bone 
surface was 7±3% of the scaffold’s ROI. This resembled a pore fill percentage of 18±6%. 
After two and ten weeks of implantation, the macroporosity was not significantly changed 
in both groups. 
bone surface 
(% of Roi)
Pore fill (%)
Porous Ca-P 0 ± 0% 0 ± 0%
Porous Ca-P + rhBMP-2 7 ± 3% ** 18 ± 6% **
TABLE 3: Histomorphometrical analysis of ectopic bone formation after 10 weeks of implantation
(means ± standard deviation for n=9 ** p<0.05). 
FIGURE 4:
Results of fluorescence microscopy inside a fluorochrome labelled rhBMP-2 loaded Ca-P cement (10 weeks). 
Formation of bone started at the cement surface and proceeded into the macropore. C=calcein label, 
administered after seven weeks of implantation (green). T=tetracycline label, administered after nine weeks 
of implantation (yellow). (original magnification 20x).
←
←
Calcein
Tetracycline
Cement
Pore
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DiSCUSSioN
In this study, we investigated the osteoinductive characteristics of rhBMP-2 loaded and 
unloaded porous preset Ca-P cement discs at an ectopic site in rabbits. As reference 
material, rhBMP-2 loaded ACS discs were implanted similarly. 
After two and ten weeks, implants were retrieved from their subcutaneous pockets. All 
Ca-P discs had maintained their shape and stability. This observation suggests that the 
mechanical properties of this porous Ca-P cement are sufficient to serve as scaffold 
material for subcutaneous bone engineering. On the contrary, none of the ACS discs could 
be retrieved. Despite widespread searching, no ACS residue or subcutaneous bone 
formation were observed. Bone formation in the vicinity of the tattoo could not be 
confirmed histologically. Therefore, we conclude that the ACS has been degraded 
completely within two weeks. This rapid degradation of the ACS sponge was also observed 
in the cranial defect study that was performed in the same rabbits.31 In contrast to studies 
dealing with rhBMP-2 loaded ACS in subcutaneous pockets in rats28,32, ectopic bone 
formation was not observed in the rhBMP-2 loaded ACS implants. We assume that the 
absence of bone formation in the current study is due to the spongy nature of the ACS, 
which causes rapid dispersion of the rhBMP-2 directly after implantation. This explanation 
is supported by the findings of Friess et al33, who reported that the fraction of rhBMP-2 
retained in the ACS in subcutaneous sites is less than 10% after 10 days, which is perhaps 
too low to induce bone formation. Further the implantation site could have an effect on 
ectopic bone formation. For example, Yoshida et al described that subcutaneous 
implantation is less favorable for rhBMP-2 induced bone formation compared to 
intramuscular or intermuscular implantation.24 This suggests that although rhBMP-2 
loaded ACS is a powerful osteoinductive material in other locations34,35, it could be less 
suitable for subcutaneous prefabrication of bone graft substitutes. 
Histomorphometrical analysis determined that bone formation in the rhBMP-2 loaded 
porous Ca-P cement discs reached a pore fill of 18 ±6% after ten weeks of implantation. As 
the two weeks light microscopical sections did not show bone deposition or cartilage 
formation, and the three weeks fluorescent Alizerin-Complexon label was never observed, 
it could be supposed that direct bone formation started after three weeks of implantation. 
Some studies even suggested that calcium phosphate biomaterials show osteoinductive 
characteristics in soft tissues without administration of growth factors or osteoblastic 
cells.36,37 However, this suggestion could not be confirmed by the present study because 
unloaded porous Ca-P cement discs did not show any bone formation after subcutaneous 
implantation up to ten weeks. 
The sequence of the fluorescent labels also confirmed that bone formation started at the 
cement surface and subsequently proceeded into the center of the macropores. This 
observation agrees with previously reported bone deposition in porous ceramics31,38 and 
illustrates the osteocompatibility of porous Ca-P cement. Furthermore, it is opposite to 
bone formation in other scaffold materials like titanium fiber mesh, which is reported to 
start in the center of the pore.39,40
Finally, histomorphometrical analysis included quantification of the cement surface as 
indicator of macroporosity and implant degradation. Degradation of the cement was not 
observed in this study. In previous studies, degradation of similar porous Ca-P cement 
varied from none to 80% after ten weeks.13,31 It is known that the presence of bone –and 
thus osteoclasts- is essential for degradation of Ca-P material. Ideally, bone formation and 
scaffold degradation follow one another progressively until the biomaterial has been 
replaced completely by new bone. As long as bone formation is not extensive enough to 
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supply mechanical strength, the scaffold material should not be degraded too quickly to 
assure stability of the construct. We think that the limited extent of bone formation in the 
rhBMP-2 loaded Ca-P cement discs after ten weeks does not justify significant degradation 
of the Ca-P cement at this phase. Furthermore, in the orthotopic implants, no degradation 
of the porous Ca-P cement discs was observed either, while these implants showed an 
extensive bone fill up to 53.0 ±5.4%.31 This is in contrast to a previous study in goats, where 
porous Ca-P cement implants inserted in the femoral condyle showed 80% degradation 
within ten weeks.13 This illustrates that degradation of Ca-P cement depends on various 
parameters such as implant dimension, species and implantation site. 
CoNClUSioNS
In summary, we conclude that porous Ca-P cement is a suitable carrier material for 
ectopic bone engineering. Although the amount of bone formation in this study was 
limited, porous Ca-P cement in combination with rhBMP2 revealed osteoinductive 
properties and maintained its shape and stability during subcutaneous implantation in 
New Zealand white rabbits for ten weeks. 
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THE INFLUENCE OF RGD-LOADED TITANIUM 
IMPLANTS ON BONE FORMATION IN VIVO
iNTRoDUCTioN
In the field of bone regeneration, naturally derived and synthetic polymers, ceramics, 
metals and composites are being used. Occasionally, these so-called scaffold materials are 
also provided with growth factors as well as stromal cells in order to enhance their bone 
forming capacity. The demands upon the scaffold properties largely depend on the site of 
application and the function that has to be restored. For example, the ideal scaffold material 
is biocompatible and biodegradable, can be shaped easily, possesses interconnective 
porosity, is osteoconductive and promotes angiogenesis.1
Unfortunately, none of the currently used materials meets all of the properties postulated. 
Some of the materials show an undesirable inflammatory response or foreign body reaction. 
These reactions are associated with a reduced osteoinductive response. Other materials 
show a lack of structural support and good mechanical characteristics. 
In view of the above mentioned, in our laboratory a series of studies is ongoing where 
we explore the feasibility and efficacy of titanium fiber mesh as scaffold material for bone 
reconstructive purposes. Titanium is well known for its excellent biocompatibility. This is 
expressed by two major observations: (1) a very favorable response of tissues to titanium 
surfaces, and (2) the absence of allergic reactions to titanium.2,3 For example, bone cells 
and mineralized bone matrix are laid down on titanium surfaces without interposition of 
other tissues.2
The porous titanium fiber mesh as used in our studies has several advantages above 
bulk titanium, like its flexibility and interconnective porosity. Flexibility helps presumably 
to eliminate focal stresses by distributing the stresses between implant and tissue over a 
larger area.3 The porosity of the fiber mesh can be varied during the fabrication, which can 
influence the amount of bone ingrowth into the material and allows a more normal 
restoration of the bone unlike nonporous implant materials. 
Proper bone growth also requires initial stability. The frictional characteristics of porous 
titanium fiber mesh when contacting bone exceeds solid-metal materials available today. 
In the early post-operative period these frictional and structural properties allow a high 
initial stability of the construct. 
Consequently, porous titanium fiber mesh offers several advantages over other materials 
by its uniformity and structural continuity, as well as by its strength, low stiffness, high 
porosity, corrosion resistance and high coefficient of friction.4 Nevertheless, previous 
studies have shown that the osteoconductive properties of the material are still insufficient 
to allow complete closure of cranial defects in rats.5 Stromal bone marrow cells have been 
seeded into the mesh porosity to overcome this problem.5 Although the data confirmed 
that this technique supports the bone formation inside the mesh, this cell-based approach 
is laborious and the outcome not completely predictable. Therefore, titanium mesh has also 
been treated with bone growth stimulating factors, such as bone morphogenetic protein 
and transforming growth factor-ß1.6-8 Despite favorable results in rats, the disadvantage of 
the use of such morphogens is the cost and reproducibility of the results in larger animals 
and humans. 
An alternative approach to the above mentioned ones can be the coupling of ligands, 
like peptides, to the titanium mesh surface.9
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The organic component of bone is composed of numerous extracellular matrix proteins 
that serve multiple roles in bone formation and homeostasis, ranging from simple cell- 
attachment to binding of hydroxyapatite. These extracellular matrix proteins interact with a 
heterodimeric cell membrane receptor family, known as integrins that use multiple 
intracellular signaling pathways. Arginine-glycine-aspartic acid or RGD is a small peptide 
ligand, which has high affinity for these integrins and is the most extensively studied 
integrin-stimulating peptide. It is known, that RGD peptides increase the overall 
adhesiveness of the surface for osteoblasts.10,11 In this way, they can essentially mimic cell 
attachment activity of the bone cells.12,13 It has also been suggested that RGD peptide 
coating enhances titanium rod osseointegration in the rat and goat femur.14,15
In the current study, the influence of RGD peptide sequence on porous titanium fiber 
mesh and on bone formation itself was investigated. We evaluated the osteoconductive 
properties of porous titanium fiber mesh, coated with or without RGD-sequence, in a rabbit 
non-critical size cranial defect model. We hypothesized that adding this cycled RGD-
peptide to the titanium fiber mesh would enhance the osteoconductive properties of this 
carrier material. In the study design, an empty control defect was included in order to 
follow the regular healing process of the non-critical sized cranial defect.
 
MaTERialS aND METHoDS
implant preparation
Sintered titanium fiber mesh implants (Bekaert N.V., Zwevegem, Belgium) with a 
volumetric porosity of 86%, density of 600 g/m2 and fiber diameter of 40 μm were used.
The prepared implants were disc-shaped with an outer diameter of 8.0 mm, thickness 
of 0.8 mm and weight of approximately 33.5 mg. All implants were ultrasonically cleaned 
with isopropanol and 70% ethanol for 15 minutes, and then sterilized by gamma 
sterilization. A total of 60 implants were prepared.
Subsequently, 30 of the titanium discs were coated with 100 µM cyclic RGD-peptide 
(provided by Biomet Deutschland GmbH, Darmstadt) and first synthesized by the group of 
Prof.dr.H.Kessler at the TU Munich, Germany) containing a phosphonate anchor, in 
phosphate buffered saline (PBS, pH 7.4). The RGD was connected with a covalent bond, 
which creates a connection. The Titatium meshes were soaked in with the coating solution 
and the peptide was allowed to immobilize overnight. After three washes with PBS the 
meshes were dried and sterilized by gamma sterilization (≈25 kGy) and ready for 
implantation. Gamma sterilization was confirmed by the manufacturer (Biomet 
Deutschland) and was shown not to affect the activity of the peptide coating. 
Experimental study design
Thirty adult female New Zealand white rabbits (2.5-3.5 kg) were used. National 
guidelines for the care and use of laboratory animals were observed. In each rabbit three 
cranial defects with an outer diameter of 8.0 mm were made (Figure 1). The distance 
between the defects was at least 5 mm. Treatments were titanium fiber mesh (Ti), titanium 
fiber mesh loaded with RGD peptide sequence (RGD-Ti) and an open control defect to 
follow the regular healing process of the non-critical sized cranial defects.
The rabbits were sacrificed at different time-intervals of two, four and eight weeks 
(respectively, group I, II and III; Table 1), and in each case the skull with the implants was 
retrieved so that histologic evaluation could be performed.
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Group Defect size Number of defects
(RGD-Ti, Ti, open)
implantation 
time
I n=10 8.0 mm 3 2 weeks
II n=10 8.0 mm 3 4 weeks
III n=10 8.0 mm 3 8 weeks
TABLE 1: Number of animals, defect size and implantation time.
Surgical procedure
Surgery was performed under general inhalation anesthesia. The anesthesia was induced 
by an intravenous injection of Hypnorm® (0.315 mg/ml fentanyl citrate and 10 mg/ml 
fluanisone) and atropine, and maintained by a mixture of nitrous oxide, isoflurane and 
oxygen through a constant volume ventilator. To reduce the perioperative infection risk, 
antibiotic prophylaxis (Baytril 2.5%) was given to the rabbits.
After anaesthetization, the animals were immobilized on their abdomen. Hair from the 
cranium was shaved and the skin was disinfected with povodine-iodine.
From the nasal bone to the occipital protuberance, a longitudinal incision was made. 
Thereafter, a midline incision was created in the periosteum. Subsequently, the periosteum 
was removed gently and lifted from the parietal skull with a blunt instrument. Three cranial 
full-thickness bone defects with an outer diameter of 8 mm were prepared with a dental-
trephine bur at low rotation speed (1000-1500 rpm) in both sides of the parietal bone. The 
drill depth was limited to 1.5 mm and the cranial bone disks were carefully removed. 
During the drilling procedure, saline was supplied as a coolant. After this procedure, the 
RGD-Ti implant was inserted according to a randomized implantation schedule in one of 
the three defects in the skull (Table 2). The titanium fiber mesh without RGD was placed 
in the second defect (Ti). The third defect was left open as a control in order to follow the 
regular healing capacity of this non-critical sized cranial defect in rabbits (Figure 1). The 
periosteum and skin were closed (tensionless) using Prolene 4.0 sutures. 
FIGURE 1:
The three cranial full-thickness bone defects
with an outer diameter of 8 mm (RGD-Ti, Ti, 
and open).
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Rabbit no and 
location skull
RGD-Ti 
location
Ti location Control defect 
location
No defect
1, 5, 9, 13, 17, 21, 25, 29 1 2 3 4
2, 6, 10, 14, 18, 22, 26, 30 2 3 4 1
3, 7, 11, 15, 19, 23, 27 3 4 1 2
4, 8, 12, 16, 20, 24, 28 4 1 2 3
TABLE 2: Randomized implantation schedule.
Histological and histomorphometrical evaluation 
Skull bones containing the implants were retrieved for histological examination at 
the various time cited above. Directly after retrieval, skulls were fixed in 4% buffered 
formalin solution and dehydrated in a graded series of ethanol. Before embedding in 
methylmethacrylate (MMA), the skulls were divided with a sawing machine into three 
separate specimens containing one implant each. Finally, thin sections (10 μm) were 
prepared by a sawing microtome technique after polymerization.16 All sections were made 
in the frontal-caudal direction. The slides were stained with methylene blue-basic fuchsin 
and observed with a light microscope for histological examination (Leica Microsystems 
BV, Rijswijk, the Netherlands). At least three sections from the central part of each implant 
were evaluated.
Histological evaluation consisted of a concise description of the observed specimens 
and a histomorphometrical analysis of the tissue response. 
Histomorphometrical evaluation was carried out using computer- based image analysis 
(Leica® Qwin Pro-image analysis system). From each implant, the data were pooled and 
the mean used for statistical analysis.
Cranial (skull)
Caudal (skull)
1
4
2
3
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The following histomorphometrical parameters were assessed for the Ti and RGD-Ti 
cranial implants (Figure 2):
The surface area where the titanium implant was inserted (the so-called Region of 
Interest, ROI). The bone surface area in the ROI (expressed as a percentage of the ROI). 
The distance of bone ingrowth into the titanium fibre mesh. This was calculated as the 
sum of ingrowths at the right and left side of the implants divided by the total length of the 
implant.
For the open control defects only the maximum gap as left at the end of the respective 
implantation times was measured.
Statistical analysis
All measurements were statistically evaluated with GraphPad® Instat 3.05 software 
(GraphPad Software Inc, San Diego, CA, USA) using an unpaired Student t test with 
Welch correction to compare untreated Ti with RGD-treated Ti specimens for each 
implantation time. All data were tested for normality. Differences were considered significant 
at p-values less then 0.05.
 
RESUlTS
Macroscopical evaluation
All 30 animals survived the implantation period and remained in good health. At 
retrieval no macroscopic signs of inflammation or adverse tissue reaction were seen around 
any of the 90 defects. All implant sites and empty control defects could be easily located. 
Each implant remained seated at the original site and they were all covered by periosteum. 
Bone formation could be seen macroscopically in most of the specimens. The newly formed 
bone appeared normal. No gross macroscopical differences could be observed between the 
RGD-Ti and the Ti group.
                                                                                                                                                                                                                                          
= ROI
= Bone Surface Area
= Ingrowth L+R /
 Total lenght
L R FIGURE 2:
Histomorphometric parameters of Ti and RGD-Ti 
cranial implants (region of interest (ROI), bone 
surface area, and bone ingrowth in length).
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Histological and histomorphometrical evaluation 
Two weeks
All of the control defects (10) were open after two weeks. New bone formation started 
mainly at the edges of the defect (Figure 3). The morphological appearance and thickness 
of the newly formed bone differed from the original bone. Histomorphometry revealed 
that the bone had covered 52±8% of the length of the original control defect size. 
Also, none of the titanium defects were closed (covered with bone over the whole 
defect). In all Ti and RGD-Ti implants, blood vessel ingrowth and fibrous tissue formation 
were present. Blood vessel ingrowth in the RGD-Ti group appeared to be more prominent 
than in the Ti group. No inflammatory cells or fibrous tissue were present in or around the 
surface of both types of implant.
A
B
C
FIGURE 3:
Light microscopical overview of A: control defect, B: RGD-Ti scaffold, 
and C: Ti scaffold, 2 weeks postimplantion (original magnification 1.6x).
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After two weeks, 12 ± 5% of the RGD-Ti fiber mesh was covered with bone with a 
trabecular structure starting at the edges, and 8 ± 6% of the Ti fiber mesh without RGD was 
covered (no significant difference, Table 3). There was also no significant difference between 
the total ingrowth (percent ingrowth of the total length of the implant) of the RGD-Ti 
group (58 ± 24%) and the Ti group (44 ± 26%, Table 4).
area of bone / Roi (%) RGD-Ti Ti
2 weeks 12 ± 5% 8 ± 6%
4 weeks 12 ± 4% 6 ± 5%
8 weeks 18 ± 10% 10 ± 7%
TABLE 3: Bone surface area in RGD-Ti and Ti scaffolds 2, 4 and 8 weeks postimplantation.
bone-ingrowth right + left / 
Total lenght of implant (%)
RGD-Ti Ti
2 weeks 58 ± 24% 44 ± 26%
4 weeks 71 ± 17% 50 ± 20%
8 weeks 71 ± 21% 52 ± 16%
TABLE 4: Bone ingrowth (right +left) in RGD-Ti and Ti scaffolds 2, 4 and 8 weeks postimplantation. 
Representative examples of light microscopical sections of control, RGD-Ti and Ti 
implants 2 weeks postimplantation are depicted in Figure 3.
Four weeks
All of the empty control defects were still open after four weeks (n=10). The newly 
formed bone covered 52±12% of the total length of the original control defect size 
(Figure 4). The contour, i.e. thickness, of the ingrown bone differed from the original bone. 
Inside the empty defect space, fibrous tissue was present and blood vessel invasion had 
occurred. Always, a fibrous tissue capsule could be observed at the periphery of the bone 
defect. 
The Ti and RGD-Ti mesh implants were also surrounded with a fibrous tissue capsule. 
No inflammatory cells were seen in or around the surfaces of the implants. There was no 
observable increase in thickness of the capsule from week 2 to week 4. 
After four weeks there was significantly more bone surface area in the RGD-Ti group 
(12 ± 4%) compared with the Ti group (6 ± 5%, Table 3). Further, the total bone ingrowth 
in the RGD-Ti group was 71 ± 17% and in the Ti group 50 ± 20%, which is significantly 
different as well (Table 4). 
Figure 4 shows typical histological slides of the control, RGD-Ti and Ti implants.
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A
B1
C1
C2
B2
C
FIGURE 4: 
Light microscopical overview of A: control defect, B: RGD-Ti scaffold (B1 shows limited bone ingrowth; 
B2 shows bone overgrowth of mesh structure), and C: Ti scaffold (C1 shows limited bone growth; 
C2 shows deep bone penetration in mesh porosity) 4 weeks postimplantion (original magnification 1.6x).
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A
B1
C1
C2
B2
FIGURE 5: 
Light microscopical overview of A: control defect, B: RGD-Ti scaffold (B1 showth bone overgrowth; 
B2 shows bone ingrowth in mesh structure), and C: Ti scaffold (C1 shows no bone ingrowth; 
C2 shows limited bone ingrowth in mesh porosity) 8 weeks postimplantion (original magnification 1.6x).
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Eight weeks
All of the empty defects were still open after 8 weeks. New bone formation covered 
64±12% of the total length of the control defect (Figure 5). The newly formed bone still 
differed in thickness compared with the original bone. A fibrous tissue capsule was 
maintained at the outside of the gap. One of the RGD-Ti implant was completely covered 
with bone over its total length. Further, blood vessel ingrowth and fibrous tissue encapsulation 
was very comparable with the 2- and 4-week specimens. After eight weeks, 18 ±10% of the 
RGD-Ti fiber mesh surface area was occupied by bone compared to 10 ±7% of the titanium 
fiber mesh without RGD (Table 3). This difference was not significant (p=0.057). However, 
the total bone ingrowth percentage in the RGD-Ti group (71 ± 21%) was significantly 
greater than in the Ti group (52 ± 16%) (Table 4). Figure 5 shows the light microscopical 
appearance of control, RGD-Ti and Ti implants 8 weeks postimplantation. 
DiSCUSSioN
In this study, we investigated the effect of RGD coated titanium fiber mesh on bone 
formation in vivo at three different time periods. Histomorphometric analysis determined 
that 18 ±10% of the RGD-Ti fiber mesh was occupied with bone after 8 weeks compared 
with 10 ±7% of the titanium fiber mesh without RGD (not significant; p=0.057). Nevertheless, 
after 4 weeks there was significantly more bone surface area in the RGD-Ti group (12 ±4%) 
compared with the Ti group (6 ± 5%, Table 3). A significant increase in the ingrowth (length) 
after 4 and 8 weeks occurred as well, when compared to the reference material (uncoated 
titanium fiber mesh). We must also note that all control defects stayed open until 8 weeks 
postimplantation. This emphasizes the relevance of our model. Evidently, the Ti scaffolds 
also did not hamper or interfere in a negative way with the bone-healing process. 
Bone cell adhesion and migration is known to play an important role during the 
biological processes underlying bone healing and bone regeneration. Cell adhesion 
peptides, like RGD, are supposed to play a role in the control of bone cell proliferation and 
differentiation. The peptides must be covalently attached to a suitable carrier material in 
order to be used in implant surgery. The results, as obtained in the current study, confirm 
the hypothesis that coating cycled RGD-peptide on titanium fiber mesh will enhance the 
osteoconductive properties of this carrier material. The results corroborate with other 
studies. For example, Ferris et al14 demonstrated a significant increase in new bone thickness 
around RGDC (Arg-Gly-Asp-Cys) modified surfaces at polished titanium rods in a rats 
femur after 2 and 4 weeks of implantation. They measured a significantly thicker shell of 
newly formed bone around the implant as soon as 2 weeks postimplantation, but using 
another animal model and another titanium implant and implantation site. 
Elmengaard et al,17 showed that cyclic RGD coating on unloaded press-fit titanium 
implants has an osteoconductive effect only directly at the interface after 4 weeks 
postimplantation (implanted in the tibia of a dog model). Also, Schliephake et al found an 
increase in bone-implant contact from 1 to 3 months postoperatively in a group of RGD-
coated implants, using a combination of collagen and RGD on dental implants in the 
mandibles of 10 beagle dogs.18 However, similar to our study, Schliephake et al showed a 
large degree of variation in bone contact rates within the various experimental groups, 
resulting in a decreased level of significance. The experimental model can be an important 
variable for this phenomenon. Tripeptide RGD has been shown to enhance in vitro the 
adhesion and spreading of fibroblasts, endothelial cells, smooth muscle cells and osteoblasts 
when this biomolecule was grafted on different surfaces.19-22 Concerning the effect of RGD 
peptides on osteoblast cell differentiation, integrin-mediated cell binding seems to be the 
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essential parameter. In particular, αvβ3- and αvβ5 integrin selective RGD peptide ligands 
are responsible for mediating the initial adhesion and increased synthesis of mineralized 
matrix.23 Bernhardt et al also indicated that RGD peptides were capable of generating 
signals for the specific microenvironment around titanium implants in the femur of a goat 
and thus accelerated the bone formation process.15 Nevertheless, a decisive factor in the cell 
attachment-promoting activity of surface bound RGD peptide is, of course, the availability 
of a sufficient amount of free bone-forming cells. This may have been the major problem in 
our in vivo study. Periosteal osteo- and chondrogenesis is important for bone defect healing. 
In our study design, the periosteum was first lifted from the skull bone and at the end of 
the procedure was sutured back over the mesh implant to its original position. The 
periosteum consists of two layers: a fibrous outer layer and bordering to the bone a 
cambium layer, which contains specific osteogenic and chondrogenic precursor cells.24 
Therefore, maintenance of this cambium layer is essential for bone healing to occur in the 
mesh implant after closure of the periosteum at the end of the implant installation. However, 
in rabbits this layer is difficult to retain during surgery resulting in delayed healing.25 
Besides preservation of the cambium layer, skull bone is composed mainly of cortical bone 
with a minimal portion of marrow-rich cancellous bone. In addition, the amount of contact 
between the mesh scaffold and bone defect wall was limited to a few 40 µm thick titanium 
fibers due to the specific morphological structure of the mesh material. Apparently, this 
also did not promote the migration of bone cells into the mesh porosity. 
Besides the experimental model, another critical issue dealing with the modification of 
implant surfaces by peptides is the final selectivity of the peptides used. Besides bone cells, 
the adhesion of other cell types can be promoted. Also, multiple ligands may be required for 
a full cell adhesion response.26 In view of this, two relevant parameters for the final biological 
effect of grafted RGD peptides are the competitive adsorption of a second protein from the 
surrounding body fluid and the RGD peptide surface concentration.27 The second adsorbed 
protein can result in inefficient cell adhesion, and an increase in RGD peptide surface 
concentration has been shown to result in increased cell proliferation with, at the same 
time, reduced matrix production.27 Unfortunately, we do not know whether optimum 
surface conditions existed for early differentiation and phenotypic expression on our RGD-
coated titanium fiber meshes.28 In view of the above, it must also be noted that other implant 
materials are available with perhaps better osteoconductive properties as compared with Ti 
mesh. Most of these materials belong to the class of calcium phosphate (Ca-P) ceramics. 
Unfortunately, these materials lack the advantageous mechanical properties of titanium, the 
result being that titanium, with its improvement in osteoconductive behavior, is still 
attractive from the final clinical application perspective.29
CoNClUSioN
In conclusion, cyclic RGD peptide in combination with titanium fiber mesh has a 
positive effect, compared with titanium fiber mesh alone, on bone formation in vivo after 
4 and 8 weeks when implanted in the skull of New Zealand white rabbits. Nevertheless, the 
amount of bone formation inside the mesh pores was still limited and further studies are 
required to optimize the bone biological effect of cyclic RGD peptide grafted on titanium 
fiber mesh scaffold.
Acknowledgement: Biomet Deutschland GmbH provided the cyclic RGD-peptides.
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ORTHOTOPIC BONE FORMATION IN PLATELET RICH 
PLASMA (PRP) LOADED TITANIUM FIBER MESH 
PLACED IN SEGMENTAL DEFECTS
iNTRoDUCTioN
The treatment of large bone defects is challenging to orthopedic and reconstructive 
surgeons. Treatment of bone defects in weight-bearing situations (e.g. limbs) demands the 
use of a stable construct. Various techniques can be used to bridge defects or regenerate lost 
bone in these circumstances: Autogenous bone grafts, either vascularized (for example the 
free fibula flap) or non-vascularized, bridging T2-pens (intramedullairy nailing system for 
fixation of long bone fractures) and plates. More recently, tissue engineering strategies are 
being used to create Bone Graft Substitutes. This involves the use of natural or synthetic 
materials as a scaffold or matrix for cells and/or growth factors. Although these scaffolds 
improve the migration, proliferation and differentiation of the bone repair process, they do 
not possess bone-inductive activity. Growth factors can induce the formation of new bone. 
Among osteoinductive growth factors the use of Bone Morphogenic Proteins (BMPs) has 
been most extensively studied in animal and clinical models.23 Drawbacks to the clinical 
use of BMPs are the high costs and unphysiological high dose needed (milligram range).15 
An attractive alternative is the use of autologous “Platelet Rich Plasma” (PRP). Multiple 
growth factors exist in platelets: Platelet Derived Growth Factor (PDGF), Transforming 
Growth Factor beta 1 (TGFβ1) and beta 2 (TGFβ2), vascular endothelial growth factor 
(VEGF), Insuline Growth Factor (IGF) and epidermal growth factors (EGF).2,17,26 
PRP is a volume of autologous plasma that has a platelet (thrombocytes) concentration 
above baseline (1 ×109 pl / ml). These proteins act on target cells, resulting in the specific 
stimulation or inhibition of these cells. PRP can be obtained from whole blood by 
centrifugation and separation of thrombocytes with the use of a cell separator. Depending 
on the production process, the concentration of thrombocytes in PRP is 3- to 20-fold 
greater than in whole blood.17 
The positive effect of PRP can be mainly attributed to the effect of TGF-β and PDGF on 
cell proliferation, differentiation and angiogenesis. PRP stimulates the proliferation and 
differentiation of osteoblasts and proliferation of capillaries.18,21 The clinical use of platelet 
concentrates in PRP with autologous bone grafts, has been shown to nearly double the rate 
of bone formation and to enhance bone density by 20 % in some studies.17  
Recently, the efficacy of PRP combined with a polylactide scaffold and autologous bone 
graft, in goat mandibular defect model, has been demonstrated.6 The use of such scaffolds 
can further limit donor-site morbidity.  
Another scaffold material for loaded applications is titanium (Ti) fiber mesh.24,25 This 
titanium mesh has excellent mechanical properties, is bone biocompatible and easy to 
handle during surgery. The porosity of the fiber mesh can influence the amount of bone 
ingrowth into the material and allows a more normal restoration of the bone unlike 
nonporous implant materials.10 Since the application of PRP in the treatment of bone 
defects demands the presence of autologous bone graft, the titanium mesh scaffold will be 
filled with autologous bone. 
The objective of the present study is to evaluate the bone stimulative effect of PRP on 
autologous bone graft and the influence of a titanium fiber mesh scaffold in a weight-baring 
bone defect model in rabbits. It was hypothesized that PRP would have a beneficial effect 
on bone formation in autologous bone grafts placed in a titanium fiber mesh scaffold.
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MaTERialS aND METHoDS
Preparation of porous Titanium fiber mesh scaffold
Bekaert N.V. (Zwevegem, Belgium) provided the titanium (Ti) fiber mesh implants. 
The mesh implants were fabricated by interengaging and intertwining a multiplicity of 
commercially available pure titanium fibers with a fiber diameter of 45 μm. After 
compression against a solid Al2O3 rod the fiber structures were sintered to bond the fibers at their points of contact. In this way a hollow cylindrical shaped tube was created. The 
volumetric porosity of the titanium mesh was more than 86% and the weight was 120 
grams/m2. The hollow tubes had a length of 15 mm and an outer diameter of 4 mm with an 
inner diameter of 2.7 mm. Prior to the experiment, measurements were taken in an 
anatomical rabbit model of the same age to ensure the implants were sized appropriately.
Preparation of the PRP solution 
The definition of PRP is at least 1.×106 platelets/µl in 5 ml plasma.18 10 ml autologous 
venous blood of the rabbit was taken in the morning before surgery. This was centrifuged 
in a 50 ml tube (2010 RPM) in a Hettich Rotixa/ AP centrifuge (Gemini BV, Apeldoorn, 
Netherlands) for five minutes. The plasma and buffy coat were removed and placed in a 
new tube. The platelets were counted in a Coulter counter (Onyx/ Bürker) The PRP was 
centrifuged for another five minutes (3170 RPM) in a Hettich Rotixa/ AP centrifuge 
(Gemini BV, Apeldoorn, Netherlands). In total, a mixture of 1 ml PRP was created, which 
contained 1000-1500 × 109 trombocytes /l. (1.0-1.5 × 1012). Also, a substance of 10% 
calcium chloride and 300 E bovine thrombin (Fibriquick, Organon Teknika, Boxtel, The 
Netherlands) was made; 0.167 ml of this mixture was taken under sterile circumstances 
during surgery and then mixed with 1 ml PRP for 10 seconds. The clot initiator (bovine 
trombin) with an air bubble formed the PRP into a gel to optimize growth factor release. 
The PRP-gel was added to the bone chips to create a fibrin network. This substance was 
placed inside the titanium scaffold before implantation (Figure 1).
FIGURE 1:
Titanium scaffold filled with bone chips and PRP gel.
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Surgical procedure
A total of 18 adult female New Zealand white rabbits (age: three months, mean weight: 
2794 g) were used in this study. National guidelines for the care and use of laboratory 
animals were observed. Surgery was performed under general inhalation anesthesia. The 
anesthesia was induced by an intravenous injection of Hypnorm® (0.315 mg/ml fentanyl 
citrate and 10 mg/ml fluanisone) (Abbeyvet Export Ltd, Leeds, UK) and atropine, while 
maintained by a mixture of nitrous oxide, isoflurane, and oxygen through a constant 
volume ventilator. To reduce the peri-operative infection risk, antibiotic prophylaxis 
(Baytril® 2.5% (KPV Pharma, Kiel, Germany) was given to the rabbits. Preoperatively,
all the rabbits got Finadyne® (Schering-Plough, Segre, France) 0.02 mg/kg twice a day 
during two days for pain treatment. We also administered 40 ml extra fluid before surgery 
to prevent dehydration.
After induction of anesthesia, the animals were immobilized in a prone position. In 
each animal the front legs were shaved and disinfected with povodine-iodine. A 4.5 cm 
longitudinal skin incision was made at the dorsal part along the radius. After dissecting the 
muscles, the radius was exposed. The periosteum was partially pushed off and a 15 mm 
segmental defect was created in the middle of the radius using a dental drill with a diamant 
blade with continuous saline cooling. Excess bone obtained from the creation of the 
segmental defects was grinded (mean weight 0.22 g) in a bone mill (Leibinger®) to form 
bone chips. In this way, particulate autologous corticocancellous bone grafts were obtained. 
The amount of bone chips produced by the bone mill was exactly enough to fill all of the 
titanium scaffolds.
Bilateral segmental radial defects were made in all 18 animals. Three experimental 
groups were created as described in Table 1. One of each of the three implant types was 
inserted in the segmental defect of the radius (press fit) (Figure 2). A total of 36 implants 
were placed: 9 titanium fiber meshes filled with bone chips and PRP-gel (PRP-Ti-Bone) 
(Figure 1), 9 titanium fiber meshes filled with bone chips (Ti-Bone) and 18 titanium 
fiber mesh scaffolds alone (Ti) were used as controls. Implants were placed according to 
FIGURE 2:
Insertion of the titanium scaffold in the 15 mm segmental radial defect.  
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a randomization scheme (Table 1). All rabbits received a control implant (Ti) and a 
PRP-Ti-Bone or Ti-Bone implant. 
After placement of the implants the remaining periost and the muscle layers and the 
skin were closed in separate layers with a Vicryl 4.0 suture. The rabbits were sacrificed 12 
weeks postoperatively for histological, histomorphometrical and radiological evaluation.
implant Number 
of rabbits
implantation 
time (weeks)
animal number 
and side 
(Right/left) 
Group I PRP + Ti + 
bone chips
n=9 12 1L, 2R, 6R, 7L, 
9L, 10R, 13L, 
14R, 17L
Group II 
 
Ti + bone chips 
 
n=9 
 
12 3L, 4R, 5L, 8R, 
11L, 12R, 15L, 
16R, 18R
Group III Ti (control) n=18 12 1R, 2L, 3R, 4L, 
5R, 6L, 7R, 8L, 
9R, 10L, 11R, 
12L, 13R, 14L, 
15R, 16L, 17R, 
18L
TABLE 1: Design of the experiment: number of animals, defect size, implantation time and
implantation scheme.
 
Evaluation
Histological and histomorphometrical evaluation 
The entire ulna-radius complex was retrieved for histological examination at 12 weeks. 
The samples were fixed in 4% phosphate-buffered formalin solution, dehydrated in a 
graded series of ethanol and embedded in methylmethacrylate (MMA). Thin longitudinal 
sections (10 μm) were prepared (at least three per implant) with a sawing microtome 
technique after polymerization.16 These sections were stained with methylene blue/ basic 
fuchsin and examined with a light microscope for histological evaluation (Leica BV, 
Rijswijk, the Netherlands) and using a concise description of the observed specimens.
This histomorphometrical analysis was performed using computer based image analysis 
techniques (Leica® Qwin Pro-image analysis system). Measurements were taken from 
three sections per implant, and the results pooled to obtain an average for each implant, 
which was then used in the statistical evaluation. 
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The following parameters were assessed for digital analysis in the segmental 
defects (Figure 3):
•	 The surface of the area where the implant is inserted, which is called the Region 
of Interest (ROI in mm2). (Light blue; Figure 3B).
•	 The amount of bone growth into the implants of the three different groups (mm2) 
(Green; Figure 3C). 
•	 The percentage bone in the ROI (%).
•	 The amount of bone growth outside the implant (mm2) (Blue; Figure 3D). 
A
C
D
B
FIGURE 3: 
The steps of the histomorphometrical analysis. A: Histology of the Ti implant; B: Region of Interest 
(Light blue); C: Bone growth (Green); D: Bone outside the implant (Blue).
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Radiographic analysis
A medio-lateral X-ray of the ulna-radius complex was made immediately after surgery 
(day 0) and 12 weeks postoperatively. The radiographs were made with a Siemens Mobilett 
X-ray machine. Bone healing parameters such as callus formation, quality of union and 
bone remodelling were compared for the three experimental groups.
Statistical analysis
All data are reported as means and standard deviations. Measurements from the 
histomorphometrical analysis were statistically evaluated using a One-Way Analysis of 
Variance (ANOVA) test using GraphPad® Instat 3.05 software (GraphPad Software Inc., 
San Diego, CA, USA). Differences were considered statistically significant at p-values less 
than 0.05. 
 
RESUlTS
All of the 18 animals survived the surgical procedure and were able to walk within three 
hours after surgery. All rabbits remained in good health, did not loose weight and and did 
not show any wound complications. At the end of the 12 week study, all 36 implants could 
be retrieved: 9 PRP-Ti-Bone, 9 Ti-Bone and 18 Ti implants. Peroperatively, the diameter of 
the scaffold was larger than the diameter of the bone. At the time of sacrifice the diameter 
of the implant resembled the bone diameter. 
At retrieval, only one of the animals showed an adverse tissue reaction with signs of 
inflammation. An abcess was visible around the radius and titanium implant. Further, all 
titanium implants were maintained in place and clearly visible in the radius of the rabbit. 
The total ulna-radius complex could be taken out for further investigation.
Histology
No inflammatory cells or foreign body reaction was seen in all specimens, except for the 
specimens retrieved from the rabbit with the infection. A thin fibrous capsule surrounded 
all implants. Overviews of the sections of each group are shown in Figure 4.
Group I (PRP-Ti-Bone)
After 12 weeks all of the implants showed bone bridging in the titanium implant (Figure 
4A). There were no visible remnants of the bone chips. Blood vessel ingrowth was present 
throughout the implants. All implants showed trabecular bone formation. Bone ingrowth 
was observed from the defect edges. In the newly formed bone osteoblasts and osteocytes 
were clearly present. Along the original defect, the newly formed bone was in direct contact 
with the titanium surface without the presence of an intervening soft tissue layer. 
Histological analysis could not be performed in one animal (#H6R); the titanium scaffold 
could not be observed in 2 of the 3 slides due to poor quality of the thin sections. These 
implants were excluded from the histomorphometrical analysis. Macroscopically, bone 
bridging was visible outside the titanium scaffold in the majority of these implants.
109
7
Group II (Ti-Bone)
In all Ti-Bone specimens, bone formation was present over the total length of the 
implant as well as inside the implants (Figure 4B). Bone bridging was seen similar to the 
PRP-Ti-Bone implants. Bone formation was characterized by the presence of osteoblasts 
and osteocytes. Blood vessel ingrowth was present as well. In contrast to the PRP-Ti-Bone 
implants an infection was observed in one of the Ti-Bone implants, as characterized by an 
incorporated abscess. In this scaffold, little bone formation could be seen and the bone 
chips were still present. This scaffold was excluded for histomorphometrical analysis 
(#H5L).
Group III (Ti) (control group)
In total 7 of the 18 Ti-implants were excluded for further evaluation because of staining 
(n=4) and sectioning difficulties, In addition, 3 titanium implants were deformed (n=3; 
Figure 5). A total of eleven controls remained. In eight of these Ti-implants bone bridging 
was present at the surface of the entire implant similar to the image of the PRP-Ti-Bone and 
Ti-Bone implants (Figure 4C). Again, trabecular bone with the presence of osteocytes, 
osteoblasts and blood vessel ingrowth was observed in these implants. Consequently, three 
of the control defects did not show bone bridging/ did not heal after 12 weeks.
FIGURE 4: 
Stained histological sections. (original magnification 1.6). Direct apposition of bone on the rabbits radius is 
observed. A: Group 1 implant (PRP-Ti-Bone); B: Group 2 implant (Ti-Bone); C: Group 3 implant (Ti / Control).
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Histomorphometrical analysis
Histomorphometrical analysis of bone ingrowth was carried out on 8 (of the 9) PRP-Ti-
Bone and Ti-Bone implants and 11 (of the 18) control (Ti) implants. The results of the 
histomorphometrical analysis of the three groups are listed in Table 2. 
Statistical analysis of the measurements showed difference in bone surface area between 
the three different implant groups. A statistical significant difference (p<0.05) was seen 
in between the PRP-Ti-Bone group (group I) vs the Ti-Bone group (group II) (37 ± 8% vs 
25 ±6%) and PRP-Ti-Bone group (group I) vs control group (Ti) (group III) (37 ± 8% 
vs 25 ±5%) after 12 weeks of implantation. Bone/ROI percentage was similar for the 
Ti-bone and Ti (control) implants.
Groups n Roi 
(mm2)
bone surface 
area inside 
Roi (mm2)
bone/ 
Roi (%)
bone formation 
outside the 
implant (mm2)
I (Ti+PRP+bone) 8 60 (±4) 23 (±5) 37 (±8) 9 (±2)
II (Ti+bone) 8 61 (±5) 15 (±4) 25 (±6) 13 (±2)
III (Ti empty) 11 59 (±4) 15 (±3) 25 (±5) 10 (±2)
TABLE 2: Histomorphometrical results of ROI, bone surface area inside the ROI (mm2), bone/ROI (%),
bone formation outside the implant (mm2), after 12 weeks implantation time.
FIGURE 5: 
Deformity of a titanium scaffold in the control group.
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Radiographic analysis
At 12 weeks, the X-rays showed bone healing in all defects (9 out of 9) of group I and II 
(PRP-Ti-Bone and Ti-Bone). In contrast, three of the eleven defects in group III (Ti, 
control) (H12L, H13R, H18L) appeared to be still open. (Figure 6). The titanium implants 
also maintained in place on the X-rays and were clearly visible in the radius of the rabbit.
FIGURE 6A: 
Radiographic analysis; group 1 (PRP-Ti-Bone) 
vs group 3 (Ti/control). 
Post surgery (day 1).
FIGURE 6B: 
Radiographic analysis; group 1 (PRP-Ti-Bone) 
vs group 3 (Ti/control). 
12 weeks after surgery.
A
Left (PRP)
Left (PRP)
Right (Control)
Right (Control)
B
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DiSCUSSioN
Our histological findings corroborate with the findings in earlier studies and confirm 
the high compatibility of titanium mesh with bone as demonstrated by the bone ingrowth 
and absence of an intervening fibrous layer and inflammatory cells.24,25 The findings also 
confirm our earlier observations that the titanium fiber mesh has good osteoconductive 
properties as demonstrated by the bone bridging en bone ingrowth in the Ti-Bone and Ti 
implants.
Concerning the study design, it is of clinical relevance to use a critical size defect.4 One 
of the definitions of a critical size defect is the smallest defect that will not heal spontaneously 
within a certain time period. Another definition is that a CSD is a defect that has less than 
10% healing, or will not heal, within the lifetime of the animal. Other factors like age of the 
animal will influence the healing of the defect. For rabbits earlier studies defined a 15 mm 
defect of the radius to be a CSD. Nevertheless, in our experiment in eight of the eleven 
Ti- implants bone bridging was observed. The bone bridging in the Ti-only implants can be 
attributed to the excellent osteoconductive properties of the titanium fiber mesh as shown 
before.24 Further, it cannot be excluded that the model used is not a CSD. Recently, in our 
laboratory the healing of similar 15 mm radial defects, which were left untreated, was 
evaluated by micro-CT scanning. The results showed spontaneous healing of the defects at 
12 weeks. However, irrespective the critical-sized nature of our defects, a clear difference in 
bone healing response was seen for the Ti-bone-PRP implants compared with the other 
specimens. 
In the control group three titanium scaffolds were deformed. This indicates that the 
Ti-scaffold needs appropriate bone ingrowth or bone grafting in order to remain stable. The 
other implants were not deformed and all the animals were able to mobilize on the day of 
surgery without a splint.
As mentioned, a beneficial effect of the PRP on bone formation was observed. This 
effect of PRP on bone formation by autologous bone transplants in bone defects is in 
agreement with previous human and animal studies.3,8,13,14,19,20,27 Marx et al showed a 
beneficial effect of PRP on bone density (74%±11% with PRP vs 55%±8% without 
PRP) and radiographic maturation rate (1,6-2,1 times higher) in bone grafts at 6-months in 
human mandibular defects.17 Fennis et al showed that the addition of PRP improved
bone healing considerably when using cortical scaffolds filled with a particulate cancellous 
anterior iliac crest bone graft in combination in mandibular defects in goats.6,7 On the other 
hand, it has to be noticed that other studies could not confirm the positive effect of PRP 
preparations on bone formation in bone grafts. Raghoebar at al evaluated the effect of PRP 
on remodeling of autologous bone grafts for augmentation of the floor of the maxillary 
sinus and did not observe a beneficial effect of PRP on wound healing and bone remodeling 
after three months after implantation.22 However, in this study they used a small sample 
size and bone from the iliac crest. Jung et al found no beneficial of autologous PRP on the 
healing of non-critical sized cranial defects in rabbits after four weeks of implantation.12
In spite of mixing the PRP with autologous bone grafts, they left the PRP in the non-critical 
size defect.
PRP has also been applied without autologous bone grafts. For example, PRP together 
with a biodegradable gelatin hydrogel alone showed successful bone generation in an ulnar 
rabbit model.9 Dallari et al showed a beneficial effect on bone healing and remodeling
when PRP was used in combination with freeze-dried bone allografts (FDBA) with the use 
of bone marrow stromal cells (BMSC).5 Still, other studies showed no beneficial effect in 
which PRP was combined with freeze-dried mineralized bone (FMB) and freeze-dried 
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demineralized bone (FDDB) in the rabbit cranium1, or frozen or processed bone allograft 
around non-cemented titanium implants in the femoral condyles of dogs.11 
PRP is a proven source of growth factors. These growth factors act on the osteoblasts, 
osteocytes and preosteoblasts and increase the mitosis rate and stimulate the angiogenesis.18 
Due to the presence of multiple growth factors the exact contribution of each of the 
growth factors to the stimulation of bone formation remains unclear. The variation in the 
beneficial effect of PRP in different studies might be attributed to variations in composition 
of the various PRP formulations. In addition, the positive effect of PRP seems to be related 
to the survival of osteoblasts, osteocytes and preosteoblasts, which are present in the 
autologous bone grafts.12 Alternatively, these cells can be added for instance by the addition 
of bone marrow stromal cells.5 
In the present study we did not observe any adverse effects of the PRP. One of the 
advantages of the PRP is that it is autologous. However, there has been some concern about 
a possible carcinogenic effect of PRP related to the stimulation of cellular proliferation and 
its local presence in high concentrations. For PRP to be carcinogenic is very unlikely, since 
the growth factors are merely differentiation factors and not mutagens. These growth 
factors are known to act on cell membranes in order to activate internal cytoplasmic signal 
proteins, which promote normal gene expression.18 
Another consideration is the use of bovine trombine and the risk of transmitting Bovine 
Spongiform Encephalopathy (BSE) or mad cow disease. Using recombinant human 
trombine can eliminate this risk.
Possible clinical applications include the treatment of segmental bone defects in long 
bones or the mandible, bone augmentation, e.g. sinus lifting or treatment of sternal defects, 
and the fixation of dental implants. More research is needed to eliminate the conflicting 
results with different PRP preparations.
CoNClUSioN
In conclusion, we have shown that titanium fiber mesh is an excellent scaffold material 
for the application of autologous bone grafts in this present study. Moreover, we confirmed 
a beneficial effect of PRP on bone formation of autologous bone grafts in titanium fiber 
mesh scaffolds in radial defects in rabbits. 
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general conclusions
SUMMaRY aND CoNClUSioNS
Closing capacity of bone defects: scaffolds, porosity and growth factors updated. 
In this thesis we described the high need for bone graft substitutes. The main objective 
of this research was to investigate the feasibility of porous Calcium Phosphate cement 
(p Ca-P) and titanium (Ti) as a carrier material for growth factors, e.g. Bone Morphogenetic 
Protein 2 (BMP-2), in the creation of bone graft substitutes (BGS) in cranial or radial 
defects (critical and non critical sized) or at ectopical site, as created in New Zealand white 
rabbits. Besides the porosity, we hypothesized that the osteoconductive properties of 
these carrier materials could be further enhanced by Platelet Rich Plasma (PRP) 
substitution or surface treatment with the adhesion peptide Arg-Gly-Asp (RGD-peptide). 
In the first chapter, a general introduction to the current knowledge on bone formation 
as well as the use of bone engineering methods is presented. Successful and productive 
teamwork of the osteoconductive scaffold, the bone cells and the osteoinductive growth 
factors is required for bone formation. Depending on the location and the bone defect size, 
different scaffolds can be created with or without porosity, to enhance bone formation. 
A review of the literature is presented. 
In chapter two, porous Calcium Phosphate (Ca-P) cement is evaluated. Calcium 
Phosphate (Ca-P) is a well established material for bone repair. It is injectable, can be 
moulded into the required shape and is bone biocompatible. The bone biological properties 
of Ca-P cement can even be further improved by creating porosity in the material. The 
current study was aimed on the evaluation of the osteoconductive behavior of porous Ca-P 
cement in a critical sized bone defect. Therefore, circular defects with increasing sizes (6, 9, 
and 15 mm in diameter) were created in the cranium of three months old rabbits and filled 
with porous Ca-P cement implants. The total porosity of the 6, 9 and 15 mm implants was 
calculated to be 71%, 74% and 74% respectively and the average pore diameter was 150 μm. 
In addition, empty control defects were prepared. After 12 weeks implantation time the 
animals were sacrificed and radiographic, histological and histomorphometrical evaluation 
was performed. The Critical Size Defect (CSD) of this species at this location for an 
implantation time of 12 weeks was confirmed to be 15 mm. Bone was observed to be 
present over and through almost all porous Ca-P cement implants. Only, in one out of eight 
animals with a 15 mm implant, complete bone bridging of the defect did not occur. The size 
of the defect was found not to affect the total percentage of bone formation in the cement; 
(17 ± 7)%, (18 ± 6)% and (17 ± 3)% for respectively 6, 9, and 15 mm diameter implants. In 
this chapter, it is concluded that porous Ca-P cement is an excellent osteoconductive 
material in non weight bearing situations and complete bridging of a critical sized skull 
defect occurs in this rabbit model after 12 weeks of implantation.
In chapter three, porous Ca-P cement implant was used as an osteoconductive scaffold 
in segmental defects. The study was performed to evaluate the osteoconductive behavior of 
porous Ca-P cement in a supposed Critical Sized Defect (CSD) in a weight-bearing rabbit 
radius model. Furthermore, evaluation of the torque test measurement was carried out. In 
this study, increasing defect sizes of a segmental radius (5, 10 and 15 mm), were created 
bilaterally and filled with either porous Ca-P cement or left open as a control. After 12 
weeks of implantation, torque test measurements as well as histological and radiographic 
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evaluation were performed. In two of the open 15 mm control defects, bone bridging was 
visible at the radiographic and histological evaluation. Bone was observed to be present in 
all porous Ca-P cement implants (5, 10 and 15 mm defects) after 12 weeks. No significant 
differences in torque measurements were observed between the 5 and 10 mm filled and 
open control defects using the T-test. In addition the mechanical strength of all operated 
specimens was similar compared to non-operated bone samples. The torsion data for the 15 
mm open defect appeared to be lower compared to the filled 15 mm defect as well as the 
non-operated specimens. However, a significant difference could only be proven for the 
non-operated samples. Within the limitation of the study design, porous Ca-P cement 
implants demonstrated osteoconductive properties and confirmed to be a suitable scaffold 
material in a weight bearing situation. Also, this study confirmed again that a 15 mm radius 
defect is not a CSD in female New Zealand white rabbits of six month of age.
In chapter four, the osteoinductive properties of porous calcium phosphate (Ca-P) 
cement loaded with Bone Morphogenetic Protein 2 (rhBMP-2) were evaluated and 
compared with rhBMP-2 loaded Absorbable Collagen Sponge (ACS) in a rabbit cranial 
model after 2 and 10 weeks of implantation. Recombinant human Bone Morphogenetic 
Protein- 2 (rhBMP-2) is known for its osteoinductive potential in bone tissue engineering. 
Discs with a diameter of 8 mm were loaded with a buffer solution with or without 10 µg 
rhBMP-2 and inserted in 8 mm full thickness cranial defects in rabbits for two and ten 
weeks of implantation. Histological analysis revealed excellent osteoconductive properties 
of the porous Ca-P material. It maintained its shape and stability during the implantation 
time better than the ACS but showed no degradation like the ACS. Quantification of the 
porous Ca-P cement implants showed that bone formation was increased significantly by 
administration of rhBMP-2 (ten weeks pore fill: 53.0 ±5.4%), but also reached a reasonable 
amount without rhBMP-2 (43.1 ±10.4%). In this chapter the conclusion is that: 1. Porous 
Ca-P cement is an appropriate candidate scaffold material for bone engineering, 2. Bone 
formation can be enhanced by lyophilization of rhBMP-2 on the cement, 3. Degradation of 
porous Ca-P cement is species-, implantation site- and implant dimension-specific.
In chapter five, the osteoinductive capability of rhBMP-2 loaded porous Ca-P cement at 
ectopical site was evaluated. Porous Ca-P cement discs were made and loaded with rhBMP-2 
in vitro and implanted subcutaneously in the back of New Zealand White rabbits. The 
implantation period was either two or ten weeks. Histological analysis of retrieved specimens 
revealed evident bone formation in the rhBMP-2 loaded Ca-P cement discs (pore fill: 18±6%) 
after ten weeks of implantation. Bone formation occurred only in rhBMP-2 loaded porous 
Ca-P cement discs. Degradation of the Ca-P cement could not be confirmed after ten weeks 
of implantation. The scaffold maintained its shape and stability during this time period. We 
conclude that porous Ca-P cement is a suitable carrier material for ectopic bone engineering.
In chapter six, investigation of bone formation in a porous titanium (Ti) fiber mesh 
implant, which was coated with RGD-peptide, was performed. In vitro research showed 
that the peptide sequence Arg-Gly-Asp (RGD-peptide) plays an important role in osteoblast 
adhesion. Integrins, which bind specifically short peptide sequences, are responsible for 
these cell responses. In this way, information can be transmitted to the nucleus through 
several cytoplasmic signaling pathways. On the contrary, little is known about the ability of 
peptide-coated surfaces to influence cell responses in vivo. The RGD-Ti implants were 
inserted in the cranium of the rabbit and were compared with porous titanium fiber mesh 
disks without RGD-sequence (Ti) and with an open control defect. Histological and 
histomorphometrical examinations were performed two, four and eight weeks 
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postoperatively. A significant increase in bone formation or bone ingrowth was seen in the 
RGD-Ti group compared to the Ti group after four and eight weeks. All control defects 
stayed open in all three periods. It was concluded that the use of cyclic RGD-peptide in 
combination with titanium fiber mesh has a positive contribution on bone formation in 
vivo in a rabbit animal model.
In the last chapter we evaluated the effect of Platelet Rich Plasma (PRP) on bone 
formation in a rabbit segmental weight bearing radial defect model. The positive effect of 
PRP can be mainly attributed to the effect of Transforming Growth Factor  (TGF-) and 
Platelet Derived Growth Factor (PDGF) on cell proliferation, differentiation and 
angiogenesis. Purpose of the study was to evaluate the bone inductive properties of PRP 
with titanium fiber mesh and autologous bone chips in a 15 mm rabbit radial defect model. 
18 New Zealand white rabbits were divided in three groups: I: PRP with autologous bone 
(PRP-Ti-Bone), II: autologous bone (Ti-Bone), III: control group (Ti). The implants were 
placed in the radial defect for 12 weeks. After sacrifice, all specimens were harvested for 
histological, histomorphometrical and radiographic analysis. Histomorphometrical analysis 
showed that bone formation was higher in the implants with PRP (PRP-Ti-Bone: 37 ± 8%) 
than in the implants without PRP (Ti-bone: 25 ± 6% and Ti: 25 ± 5%) after 12 weeks of 
implantation. On the basis of our observations we conclude that PRP has a stimulatory 
effect on bone formation in titanium fiber mesh filled with autologous bone graft in 
segmental bone defects. Furthermore, we have shown titanium fiber mesh to be an excellent 
scaffold material for the application of autologous bone grafts with or without PRP.
Closing remarks and future perspectives
Several scaffolds can be used to analyze the influence of the growth factors used in an 
animal study. In this thesis we were focused on porous Ca-P and titanium fiber mesh as a 
carrier material and installed in rabbits. The results showed that in this rabbit model both are 
suitable carrier materials. This was proven in weight bearing (radius), in non-weight bearing 
(cranium) as at ectopical (subcutaneous) location. On the other hand, these porous scaffolds 
materials can be improved, resulting in an enhanced stability. For example, the functionality 
of porous Ca-P can be advanced by making use of nanotechnology and biomimetic 
approaches. Also, with the use of mesenchymal cell seeding and coating technique, earlier 
research proved that the amount of bone formation can be improved as well. The 
combination of the different growth factors showed positive results in bone generation. 
Bone Morphogenetic Protein (BMP-2) substitution showed significantly more bone 
formation at orthotopical and ectopical sites. Furthermore, we found an increase in bone 
formation in the experiment with the RGD-peptide sequence and the Platelet Rich Plasma 
(PRP). More knowledge about the release of these growth factors and the specific interaction 
between the different growth factors will give us important information. In this way, the 
amount of for example substituted BMP-2 can be precisely titrated, and an overkill of 
growth factors can be prevented. Besides the positive result of PRP on bone formation, the 
thrombocytes have a positive contribution at other locations as well, for instance on wound 
healing in general. It is important to find out which growth factors are responsible for these 
promising results. Also the role of synergism between the different growth factors should 
be investigated. 
In this thesis we tried to make further steps in bone engineering using a rabbit animal 
model. Of course the efficacy of bone engineering with these two scaffold materials (porous 
Ca-P and titanium fiber mesh) in combination with growth factors has to be proven in higher 
animals and humans as well. The final aim will be the creation of a (prefabricated) vascularised 
bone transplant which can be used for large (oncological or traumatological) reconstructions. 
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SaMENvaTTiNG EN CoNClUSiES
Genezingscapaciteit van botdefecten: implantaten, porositeit en groeifactoren.
In dit wetenschappelijk onderzoek beschrijven we mogelijkheden om bot te vervangen 
omdat hieraan grote behoefte bestaat bij reconstructie van botdefecten. Aangezien autologe 
bottransplantaties beperkingen en nadelen kunnen hebben, bestaat er een grote 
belangstelling voor botvervangende middelen. In het onderzoek is poreus calcium fosfaat 
(p Ca-P) en titanium (Ti) als dragermateriaal gebruikt dat al dan niet gecombineerd werd 
met groeifactoren zoals Bone Morphogenetic Protein-2 (BMP-2). Er werd dierexperimenteel 
onderzoek bij konijnen uitgevoerd, waarbij de materialen in craniale defecten (onbelaste 
situatie), segmentale defecten (belaste situatie) en ook op ectopische locatie (subcutaan) 
geplaatst werden. Behalve naar de porositeit van het dragermateriaal, werd ook onderzoek 
gedaan naar effecten van de behandeling van deze materialen met het hechtingseiwit Arg-
Gly-Asp (RGD-peptide) en trombocyten-aggregaat (Platelet Rich Plasma: PRP). 
In het eerste hoofdstuk werd als inleiding een overzicht gegeven van de diverse 
mogelijkheden op het gebied van het vervangen van bot door middel van ‘bone engineering’. 
Er is daarbij een succesvolle en productieve samenwerking nodig tussen dragermateriaal (het 
implantaat/de matrix), botcellen en groeifactoren. Afhankelijk van het defect en de locatie, 
kunnen verschillende dragers, al of niet poreus, gecombineerd worden met groeifactoren. In 
dit overzicht werd gerefereerd aan de bestaande literatuur. In de hoofdstukken hierna werden 
de studies beschreven die naar aanleiding van dit onderwerp werden uitgevoerd.
In het tweede hoofdstuk werden de osteoconductieve eigenschappen van poreus Ca-P 
onderzocht. De injecteerbaarheid, vervormbaarheid en de biocompatibiliteit zijn de 
belangrijkste voordelen van dit materiaal. Door het materiaal poreus te maken, kunnen de 
biologische eigenschappen van het materiaal verder verbeterd worden. In deze studie werden 
er in diameter oplopende defecten in het schedeldak (6, 9 en 15 mm diameter) van konijnen 
gemaakt. Deze werden gevuld met poreus Ca-P met een gemiddelde porositeit van 73%. Ter 
controle werden ook defecten gecreëerd welke open gelaten werden. Twaalf weken na 
implantatie werden de Ca-P implantaten met omringend botweefsel uitgenomen en werd er 
radiologisch, histologisch en histomorfometrisch onderzoek gedaan. De kritische defect 
grootte (CSD), een defect dat spontaan niet dichtgroeit, bleek bij dit diermodel 15 mm te zijn 
na een implantatietijd van 12 weken. Botvorming in en over het Ca-P implantaat werd in 
vrijwel alle situaties gezien. Alleen bij één van implantaten uit de 15 mm groep trad volledige 
sluiting van het defect op. De grootte van het defect beïnvloedde in het geheel niet de mate 
van botvorming in het Ca-P cement (17 ± 7)%, (18 ± 6)% and (17 ± 3)% voor respectievelijk 
6, 9, and 15 mm diameter implantaten. De conclusie van dit hoofdstuk was dat poreus Ca-P 
een uitstekend osteoconductief materiaal is in een onbelaste situatie en dat het gebruik van dit 
materiaal tot volledige sluiting leidt van een CSD 12 weken na implantatie. 
In het derde hoofdstuk werd gekeken naar de osteoconductieve eigenschappen van 
poreus Ca-P in een belast radiusmodel bij het konijn. Deze studie werd gedaan om de 
osteoconductieve eigenschappen van poreus Ca-P cement in een te verwachten ‘Critical 
Size Defect ‘(CSD) te evalueren. Er werden bilaterale, in grootte oplopende segmentale 
radius defecten (5, 10 en 15 mm) aangebracht, welke aan één kant gevuld werden met 
poreuze Ca-P implantaten. Als controle werden de contralaterale kanten open gelaten. Na 
12 weken implantatie werd een evaluatie van de torquetest gedaan, gecombineerd met 
radiologische en histologische analyse. Na 12 weken werd er in twee van de open controle 
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15 mm defecten sluiting van het defect door ingroei van bot waargenomen (zowel 
radiologisch en histologisch). Botvorming werd aangetoond in alle poreuze Ca-P cement 
implantaten (5, 10 en15 mm defecten). Een T-test liet zien dat er geen significante verschillen 
bestonden tussen de poreuze Ca-P groep en de controle groep (5 mm: p=0.13, 10 mm: 
p=0.71, 15 mm: p=0.11). De mechanische kracht op de radii van alle geopereerde dieren 
was gelijkwaardig aan de niet-geopereerde botten. De torquetest resultaten van de 15 mm 
open defecten waren lager dan de 15 mm defecten met poreus Ca-P implantaten en de niet 
geopereerde radii. Echter, er werd alleen een significant verschil aangetoond met de niet 
geopereerde radii. Ondanks de beperkingen van deze studie werd bewezen dat poreus Ca-P 
goede osteoconductieve eigenschappen heeft in een belast radiusmodel. Ook werd er 
geconstateerd dat 15 mm defecten, in de radius van een vrouwelijke ‘New Zealand white 
rabbit’ van 6 maanden oud, geen CSD zijn. 
In het vierde hoofdstuk werd gekeken naar de botgroei bevorderende eigenschappen van 
poreus Ca-P cement dat geladen was met een botgroei bevorderende factor, te weten 
recombinant humaan Bone Morphogenetic Protein 2. Er werden daartoe defecten gecreëerd 
in het schedeldak van konijnen. Het van rhBMP-2 voorziene Ca-P implantaat werd in dit 
defect aangebracht. Dit werd vergeleken met defecten die gevuld waren met een collageen 
spons (ACS) welke ook voorzien was van rhBMP-2. Als controle werden er ook poreuze Ca-P 
implantaten zonder rhBMP-2 aangebracht. Na een implantatietijd van 2 en 10 weken, werd 
histologisch onderzoek gedaan. Conclusie van deze studie was dat poreus Ca-P een goed 
dragermateriaal voor rhBMP-2 is. Tevens werd er een significante toename van de botvorming 
gezien in de rhBMP-2 groep. Tot slot werd aangetoond dat de degradatie van poreus Ca-P 
afhankelijk is van het gebruikte proefdier, de implantaat locatie en de implantaat grootte.
 In het vijfde hoofdstuk werd gekeken naar de osteoinductieve capaciteit van poreus 
Ca-P voorzien van rhBMP-2 (zoals in hoofdstuk 4 beschreven). De implantaten werden 
subcutaan in de rug van konijnen geplaatst gedurende 2 en 10 weken. De Ca-P implantaten 
werden vergeleken met collageen spons (ACS) welke ook voorzien was van rhBMP-2. Ter 
controle werden ook poreuze Ca-P implantaten zonder rhBMP-2 geïmplanteerd. 
Lichtmicroscopisch onderzoek liet zien dat na 10 weken bot aanwezig was in de poreuze 
Ca-P implantaten welke voorzien waren van rhBMP-2. Degradatie van het cement kon niet 
worden aangetoond. Het implantaat behield zijn vorm en stabiliteit gedurende deze periode. 
Opnieuw werd geconcludeerd dat poreus Ca-P cement een goed materiaal is voor ‘bone 
engineering’ en dit keer ook op een ectopische locatie waar dus normaliter geen bot 
aanwezig is. Op deze wijze kunnen in de toekomst geprefabriceerde lappen in combinatie 
met botvervangende middelen worden ontwikkeld voor botreconstructieve doeleinden. 
In het zesde hoofdstuk werd onderzoek gedaan naar het hechtingseiwit Arg-Gly-Asp 
(RGD-peptide). Eerder in vitro onderzoek toonde namelijk aan dat deze aminozuursequentie 
een belangrijke rol speelt in de hechting van botcellen. In deze studie werd poreus titanium(Ti) 
vezelgaas voorzien van RGD peptide. Deze implantaten werden in schedeldakdefecten (8 
mm) bij konijnen geplaatst en vergeleken met titanium vezelgaas zonder RGD-peptide en 
een open controle defect. Er werd histologisch en histomorfometrisch onderzoek gedaan na 
2, 4 en 8 weken. De resultaten toonden een significante toename in botvorming aan in de 
RGD-Ti groep vergeleken met de ongeladen Ti groep na 4 en 8 weken implantatie. Alle open 
controle defecten bleven in deze drie termijnen open. Concluderend levert RGD-peptide 
een positieve bijdrage aan de botvorming, wanneer dit is aangebracht op titanium vezelgaas 
bij een implantatieduur van 4 en 8 weken in het schedeldak van het konijn. 
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In het laatste hoofdstuk werd het effect van Platelet Rich Plasma (PRP) op botingroei in 
een 15 mm segmentaal radiusdefect bij konijnen onderzocht. PRP is een trombocyten-
aggregaat dat uit autoloog bloed verkregen wordt. Het is bekend dat hierin veel verschillende 
groeifactoren zitten die een positief effect op de botgenezing kunnen hebben. De PRP werd 
geoogst uit het bloed van het te opereren konijn en werd gemengd met autoloog 
bottransplantaat, waarna dit mengsel werd aangebracht in kokertjes die van titanium 
vezelgaas vervaardigd waren. Naast deze Ti-PRP-bot groep werden er ook titanium kokers 
met alleen autoloog bottransplantaat zonder PRP (Ti-bot) en lege Ti kokertjes (Ti) in de 
defecten geplaatst. Alle drie de groepen werden na 12 weken geanalyseerd middels 
histologisch, histomorfometrisch en radiologisch onderzoek. Na 12 weken werd er 
significant meer bot gezien in de Ti-PRP-bot groep (37 ± 8%) in vergelijking met de 
implantaten zonder PRP (Ti-bot: 25 ± 6% en Ti: 25 ± 5%). Verder bleek titanium vezelgaas 
een goed dragermateriaal te zijn voor dit belaste radius model in het konijn.
afsluitende opmerkingen en toekomstperspectieven:
Verschillende dragermaterialen kunnen worden gebruikt om de invloed van 
groeifactoren op botvorming te analyseren. In dit onderzoek hebben wij ons gericht op de 
implantaten poreus Ca-P en poreus titanium vezelgaas. De resultaten laten zien dat in een 
konijnendiermodel beide materialen aan het doel voldoen zowel op belaste locatie (radius), 
onbelaste locatie (schedeldak), als op ectopische locatie (subcutaan). Verbetering voor met 
name het poreuze Ca-P zou bereikt kunnen worden door het verstevigen van dit materiaal. 
Ondanks het feit dat deze fragiele implantaten zich zelfs op gewichtsdragende locaties 
konden handhaven, is de verwachting dat met behulp van nanotechnologie en een 
biomimetische benadering de functionaliteit van het dragermateriaal nog verder verbeterd 
kan worden. Ook is het mogelijk de implantaten in vivo met cellen te laden waardoor er, 
zoals eerder beschreven, meer botvorming verkregen wordt. 
De combinatie met verschillende groeifactoren liet positieve resultaten zien wat betreft 
de botaanmaak bij de BMP-2 substitutie op zowel orthotopische (schedeldak) als ectopische 
(subcutaan) locatie. Eveneens zagen we een significante toename van bot bij de experimenten 
met gebruik van RGD-peptide en trombocyten-aggregaat (PRP). 
Verdere analyse van de ‘release’ van deze groeifactoren en de specifieke werking van de 
verschillende groeifactoren zou veel extra informatie kunnen geven. Op deze wijze zou de 
hoeveelheid van toegediende BMP-2 beter gedoceerd kunnen worden. Met name de exacte 
werking en concentraties van de multipele groeifactoren die aanwezig zijn in PRP, is iets 
wat verder uitgezocht zal kunnen worden. Op deze manier zou dit na verder onderzoek 
kunnen leiden tot meer precieze dosering, waardoor overdosering vermeden kan worden. 
Dat PRP behoudens bij de botgenezing in vivo op velerlei andere locaties (zoals bij 
wondgenezingsstoornissen) positieve resultaten geeft, laat zien dat dit trombocyten-
aggregaat veel potentie heeft. Ook de samenwerking tussen verschillende groeifactoren 
(synergisme) dient nader geanalyseerd te worden. 
In dit onderzoek hebben we ons gericht op het konijn als diermodel. De effectiviteit van 
botgenezing met behulp van poreus Ca-P en titanium vezelgaas in combinatie met 
groeifactoren zal onderzocht moeten worden bij hogere diersoorten en mensen. Het 
uiteindelijke doel zal zijn om een gevasculariseerd bottransplantaat te vervaardigen (al dan 
niet met het gebruik van prefabricatie) wat bij grote, vaak oncologische of posttraumatische, 
reconstructies toegepast kan worden.
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Afdeling Groningen: Lief oud huis- en clubgenoten. Jullie zijn altijd betrokken en 
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Afdeling Nijmegen: Lien, Eus, Oele, Marie-Jeanne, Monique en Hanneke. Dank voor 
de alweer ± 30-jarige vriendschap en steun! Ik verheug me op al het leuks dat nog gaat 
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Onze oppassen Riet, Greetje en natuurlijk mam, zonder jullie kon dit niet! Het is het aller 
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